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ABSTRACT
Hydramycin is an antitumor antibiotic isolated from Streptomyces violaceus. It is a
pyranoanthraquinone-type antitumor agent that has shown broad-spectrum activity against a
variety of human-derived cancer cell lines. Among tumors evaluated at the National Cancer
Institute (lung, colon, melanoma, breast and prostate), GI50s were <10−10 M in the NCI's 60-cellline panel. We embarked on the synthesis and evaluation of a simplified congener 2-(1-hydroxy1-(oxiran-2-yl)ethyl)-4H-naphtho[2,3-h]chromene-4,7,12-trione(17), which would facilitate
synthesis while retaining the potent activity. Hydramycin has two chiral centers, and our goal is
to design and synthesize all the possible enantiomers (four in total) for the congener of
hydramycin 17 in order to ascertain which of the enantiomers is responsible for the observed
antitumor activity. The use of enantiospecific techniques such as the Sharpless epoxidation was
initially tried to introduce the chiral centers at a later stage during the multi-step synthesis and
obtain the required pure enantiomers. Due to some limitations observed with this technique and
many other asymmetric epoxidation techniques which utilize very substrate-specific ligands, we
then modified the synthetic scheme to use another procedure, the Sharpless asymmetric
dihydroxylation in order to obtain two of the pure enantiomers of this congener of hydramycin.
The other two enantiomers are selectively obtained using the Sharpless asymmetric
dihydroxylation procedure via cyclic sulfate intermediates, followed by a modified irreversible
Payne rearrangement procedure. These routes then allowed us to obtain separately all four
stereoisomers, each having more than 90% ee as determined on chiral columns with HPLC. The
four stereoisomers have been fully characterized and will then be tested separately to ascertain
which of the isomers is responsible for the observed antitumor activity.
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I. INTRODUCTION
A. Anthraquinones
Anthraquinone, also referred to as anthracenedione or dioxoanthraquinone, is a polycyclic
aromatic compound that belongs to the largest class of naturally occuring quinones. These
compounds are generally of polyketide origin.1 Their structure is made up of three fused rings
which involve two aromatic rings and a central ring containing two opposing carbonyl groups at
positions 9 and 10 (Figure 1). Anthraquinones are widespread in nature as physiologically active
constituents of plants (aloe, cascara segrada, senna and rhubarb), microorganisms, insects, and
marine animals.2 Several methods have been developed to synthesize anthraquinones. One of the
most commonly used method involves the oxidation of anthracene (Figure 2), and a wide range of
oxidizing agents have been used for this process. Some representative examples of oxidizing
agents used are KI-TBHP, CrO2, KMnO4 and PhI/RuCl3/Oxone (Scheme 1).3-6 Other methods
have been developed to prepare anthraquinones, and these include the Friedel Crafts reaction
between benzene and phthalic anhydride Scheme 2), and the Diels Alder reaction between 1,4benzoquinone and cis-1,4-butadiene (Scheme 3). Recently, various other efficient methods have
been developed ranging from [2+2+2] cycloadditions7 to ring-closing metathesis using Grubbs’
catalyst. 2

1

Scheme 1: Oxidation of anthracene to anthraquinone.

2

Scheme 2: Friedel Crafts reaction between benzene and phthalic anhydride to form
anthraquinone.

Scheme 3: Diels alder reaction between 1,4-benzoquinone and cis-1,4-butadiene to form
anthraquinone.

B. Anthraquinone derrivatives and their applications
One of the most important applications of anthraquinones is the use of its derivatives as
dyes. Examples of the most common dyes that are derivatives of anthraquinones include alizarin
(Figure 3), 1-nitroanthraquinone (Figure 4) and anthraquinone-1-sulfonic acid (Figure 5).8,9
Alizarin, a constituent of the madder plant, is a distinctive red dyestuff which was used to dye
the “redcoats” of the British army, and in 1869 it was the first natural pigment to be produced
synthetically.10 Anthraquinone derivatives also have very interesting biological activities and
have therefore been used in drug manufacturing as exemplified by the antitumor agents
ametantrone (Figure 6), mitoxantrone (Figure 7) and the natural product adriamycin (Figure 8).2

3

4

C. Pyranoanthraquinone and related biological activity
Pyranoanthraquinones are one of the most ubiquitous class of anthraquinones. They are
also known as 4H-anthra[1,2-b]pyran-4,7,12-triones (Figure 9). The biosynthesis of the
pyranoanthraquinone type compounds have been investigated, and the anthra[1,2-b]pyran part of
the ring originates from a polyketide as shown in Scheme 4.11

Figure 9: 4H-Anthra[1,2-b]pyran-4,7,12-triones

Scheme 4: Biosynthesis of pyranoanthraquinone type compounds from polyketides.

This class of anthraquinones has shown interesting antitumor and antimicrobial activities.
Some examples of antitumor agents in the class of pyranoanthraquinones which were isolated
from natural products are pluramycin A (Figure 10), isolated from Streptomyces

5

pluricolorescens, kidamycin (Figure 11), isolated from Streptomyces phaeoverticillatus, and
hedamycin (Figure 12), isolated from Streptomyces griseoruber.11

6

D. Hydramycin
Hydramycin (Figure 13), an antitumor antibiotic agent, was isolated from the
fermentation broth of Streptomyces violaceus P950-4 (ATCC53807).12 This compound was
recovered from the cultured broth by solvent extraction and purified by a series of
chromatographic steps. It has yellowish orange crystals having a characteristic UV absorption
and was shown to have a novel structure related to the chromophore moiety of the pluramycin
group of antibiotics. In addition to its strong antibacterial activity against Gram-positive
bacteria, hydramycin exhibited potent cytotoxicity to B16 melanoma and Moser cells and
induced a significant prolongation of survival time of mice bearing P388 leukemia.12 To date,
there is no published data that defines its absolute stereochemistry.

Figure 13: Hydramycin

7

E. Mode of action of antitumor agents having hydramycin-like structures
The mode of action of most compounds similar to hydramycin in structure such as
kapurimycin A3 (Figure 14) has been extensively studied and initial in vitro studies revealed that
kapurimycin causes single-strand cleavage of supercoiled pBR322 DNA.13 Kapurimycin A3
binds to calf thymus DNA at 4 oC as shown in Figure 15, and the thermal treatment of this
adduct results in the release of a guanine covalently attached to the epoxide of kapurimycin via
one of its nitrogen atoms. Thus, the epoxide is the alkylating functional group of kapurimycin,
and this is consistent with the lack of DNA cleaving and cytotoxic activities for 14,16-deoxy14,16-dihydroxykapurimycin (Figure 16).13 These findings further revealed that DNA strand
scission by kapurimycin is due to the alkylation of guanine by ring opening of the epoxide group
of kapurimycin, depurination of modified guanine, and presumably subsequent hydrolysis of the
phosphate ester backbone at the resultant apurinic sites.14
Furthermore, the site of alkylation of the guanine was confirmed by comparative NMR
studies with N-7 methyl guanine (Figure 17) in dmso-d6.15

8
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The modes of action of other anthraquinone-type antitumor compounds have also been
extensively studied. In vivo and in vitro experiments suggest that mitoxantrone (Figure 7)
metabolism and clearance proceed via numerous oxidized intermediates.16 Interestingly,
mitoxantrone shows particular effectiveness against tumors (myeloid, leukaemia, breast and
ovarian carcinoma) that express high titers of heme peroxidases. Therefore, peroxidase-catalyzed
mitoxantrone oxidation may be important for in vivo drug activation, and the resulting
metabolites could actually be the causative agents for its cytotoxic effects.16 Additionally,
epoxy anthraquinone derivatives (EAD) have been proven to be multiple DNA target agents.17
This was confirmed by performing microarray gene expression analysis to monitor the impact of
these agents on a neuroblastoma cell line and using the connectivity map (cMAP) to explore the
putative mechanism of action of unknown drugs. From these studies, it was revealed that the
signature epoxy anthraquinone derrivatives matched the profiles of multiple known DNA
targeted agents (topoisomerase I/II inhibitors, DNA intercalators, and DNA alkylation agents) as
predicted by its structure.17.

10

F. Hydramycin and antitumor activity
Hydramycin was tested for in vitro cytotoxicity against murine and human tumor cells,
for inhibition and in vivo antitumor activity in mice using mitomycin C as a reference. B16-F10
(murine melanoma), Moser (human colon carcinoma) and HCT-116 (human colon carcinoma)
cells were grown, and the cytotoxic activities against the above tumor cell lines were determined
colorimetrically at 540 nm after staining viable cells with neutral red. The observed results
revealed that cytotoxicities of hydramycin were quite potent against these tumor cells and were
approximately 300 600 times superior to those of mitomycin C (standard) in terms of IC50
value.12 Also, inhibitory effects of hydramycin on macromolecule (DNA, RNA and protein)
synthesis were determined in vitro and found to be very active.12 Furthermore, hydramycin
demonstrated relatively broad and moderate chemotherapeutic activity against P388 leukemia.
Hydramycin being an EAD and due to its similarity in structure to antitumor agents like
Kapurimycin A3 whose mode of action has been extensively studied, can be considered as a
multiply DNA targeted agent. Therefore it should act as a topoisomerase I/II inhibitor, DNA
intercalator, and DNA alkylation agent.
The antitumor activity for hydramycin required that the total synthesis of hydramycin be
considered. Due to the complicated substitution pattern on the anthraquinone ring, we have
embarked in the synthesis of relatively simple congeners of hydramycin, which will facilitate
synthesis while hopefully retaining the observed antitumor activity. Two racemic pairs of
separable diastereomers with a methyl group on the pyranone ring 17A /17A’ and 17B/17B’
(Figure 18) have been synthesized in our laboratory and shown to be quite active against a broad
spectrum of human-derived tumors in vitro.
11

Figure 18: Structure of racemic pairs of hydramycin congeners (17A/17A’ and 17B/17B’).

Additionally, two other racemic pairs of separable diastereomers with a CH2OH group on
the pyranone ring 50A/50A’ and 50B/50B’ (Figure 19) have been synthesized in our laboratory
and are also shown to be quite active.

12

Figure 19: Structure of racemic pairs of hydramycin congeners 50A/50A’ and 50B/50B’.

13

Associated with the interesting biological activity was some selectivity which was
observed with each of the racemic pair of diastereomers. For the congener 17, the racemic pair
17A/17A’ was more potent than 17B/17B’. Similarly for the congener 50, the racemic pair
50A/50A’ was more active than 50B/50B’. The results are summarized in Table 1 below.
Lungb
1.00E-10
5.75E-08
3.96E-07
3.29E-08
4.73E-07

Hydramycin
Diast 17A/17A’
Diast 17B/17B’
Diast 50A/50A’
Diast 50B/50B’
a
NCI protocol.
b
Non-small cell lung A549/ATCC
c
Colon HCT-15
d
Melanoma LOX IMVI
e
Ovarian NCI/ ADR-RES
f
Prostate PC-3

Colonc
<1.00E-10
4.62E-08
2.75E-07
5.40E-08
1.16E-06

Melanomad
<1.00E-10
<1.00E-08
1.09E-08
3.87E-08
4.94E-07

Ovariane
<1.00E-10
4.95E-08
2.60E-07
5.79E-08
5.62E-07

Prostatef
<1.00E-10
3.15E-08
1.19E-07
4.87E-08
1.46E-06

Table 1: Antitumor activities of hydramycin and hydramycin congenersa
The selectivity observed with the racemic pair of diastereomeric congeners mandated the
design and total synthesis of the enantiomerically pure versions of these congeners. This should
enable us ascertain which of the enantiomers is responsible for the observed activity. Also, the
fact that the congeners are being tested as racemic mixtures, there could be the possibility of one
enantiomer hindering the activity of the other or one enantiomer being active while the other is
toxic, as has been the case with some commercially available drugs such as racemic albuterol
used as a treatment for asthma. In this example, (R)-albuterol is responsible for the observed
biological activity, while (S)-albuterol is toxic and therefore problematic to humans.18
Hydramycin has two chiral centers, and our goal was to design and synthesize all the possible

enantiomers (a total of four) for the congeners of hydramycin in order to ascertain which of the
enantiomers is responsible for the observed antitumor activity.
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In this dissertation I present the asymmetric total synthesis of all four enantiomerically
pure versions of hydramycin congener 17 as shown in Figure 18. This should enable us to
ascertain which of the enantiomers is responsible for the observed antitumor activity and also
enable us to determine if the presence of the less active enantiomer in each of the racemic
mixtures tested could be hindering the activity of this congener.

15

II. STAEMENT OF THE PROBLEMS
A. Synthetic challenges
Previously, Dr. Sarah Headrick and Dr. David White had designed and successfully
synthesized the racemic pair of hydramycin congener 17. There were various synthetic
challenges involved with the synthesis. The first challenge involved the synthesis of the
anthraquinone system. The second challenge involved the incorporation of the pyranone ring.
Two routes were investigated to incorporate the pyranone ring into the anthraquinone system.
Route A involved generating an enolate ion on the anthraquinone moiety, coupling it to an ester
by claisen condensation, followed by the ring-closure reaction which involves a cyclization
reaction followed by a dehydration reaction as shown in Scheme 5 below.

Scheme 5: Route A showing the synthesis of the pyranone ring via enolate formation.
Route B involved coupling an alkyne to the aldehyde containing the anthraquinone. The next
step involved an allylic oxidation reaction, which was followed by a cyclization reaction as
shown in Scheme 6 below.

Scheme 6: Route B showing the synthesis of pyranone ring via alkynone formation.
16

The synthesis of the asymmetric versions of hydramycin congener 17 had numerous
challenges involved with the introduction of the chiral centers. The use of enantiospecific
techniques such as the Sharpless asymmetric epoxidation (SAE) was initially tried to introduce
the chiral centers and obtain the required pure enantiomers, but due to some limitations observed
with this technique and many other asymmetric epoxidation techniques which utilize very
substrate-specific ligands, we could not obtain the expected results, and the scheme had to be redesigned several times before finally achieving success using the Sharpless asymmetric
dihydroxylation reaction.
Another synthetic challenge involved in the synthesis of asymmetric congener 17 was
the formation of enantiospecific anti diols. This was a very challenging problem because the
ligands, which are being used to install the chiral centers enantiospecifically, can only install
them in a syn fashion. Inverting the stereochemistry of a secondary hydroxyl group in the
presence of an adjacent tertiary hydroxyl group proved to be very challenging (Scheme 7).

Scheme 7: Inversion of configuration on a secondary alcohol in the presence of a tertiary
alcohol.
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B. Research plan and general retrosynthetic strategy
Due to the challenges involved with using the SAE approach, the initial scheme was
modified in order to use another Sharpless procedure, which is the Sharpless asymmetric
dihydroxylation (SAD) to obtain two of the pure enantiomers of the hydramycin congener 17.
The other two enantiomers are selectively obtained still using the Sharpless asymmetric
dihydroxylation procedure via cyclic sulfate intermediates, followed by a modified irreversible
Payne rearrangement procedure. The retrosynthetic pathway employed in the synthesis of this
asymmetric hydramycin congener 17 uses the the alkynone route to obtain the pyranone ring as
shown in Scheme 8 below.

18

Scheme 8: Retrosynthesis of asymmetric hydramycin congener 17.

19

C. Dissertation summary
At least one of the enantiomerically pure versions of hydramycin congener 17 is
anticipated to have a better activity than the racemic mixture due the selectivity involved in
interacting with the DNA targets. This dissertation will cover the challenges and solutions
involved in the design and synthesis of the four enantiomerically pure isomers of hydramycin
congener 17, and then provide a synthetic scheme for the future work towards the asymmetric
synthesis of hydramin itself.

20

III. DISCUSSION
A. First attempt for the synthesis of asymmetric hydramycin congener 17
The first attempt for the synthesis of asymmetric hydramycin congener 17 using
the retrosynthetic process is shown in Scheme 10. The synthetic scheme derived from this
retrosynthesis was designed and used by Dr. Sarah Headrick to synthesize the racemic
version of this congener. In the synthetic scheme derived from this retrosynthesis, the
last step, which was initially the epoxidation reaction using m-CPBA, was modified to
use the Sharpless asymmetric epoxidation reaction, in order to selectively react with a
single enantiomer of intermediate 56 and provide the epoxide with high stereoselectivity.
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Scheme 10: Retrosynthesis for first trial of the asymmetric synthesis of congener 17.
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Scheme 11 shows the synthesis of the aldehyde intermediate 10. The starting material for
this scheme is the commercially available material 1-hydroxyanthraquinone (52). Reaction of the
OH group of 52 with allyl bromide in the presence of K2CO3, and KI in DMF under reflux
provided the allyl ether 7.19 This was followed by a Claisen rearrangement reaction using
Na2S2O4 in a 1:1 DMF:H2O to yield 8 in quantitative yield.19,20 The next step was an
isomerization reaction that involved a shift in the double bond of intermediate 8 from a terminal
alkene to an internal alkene 9. This was successfully achieved in quantitative yield using
bis(acetonitrile)dichloropalladium(II).21,22 The aldehyde was easily obtained by ozonolysis,
which involved bubbling ozone gas through a solution of 9 in dichloromethane at -78 oC.19 The
NMR spectra of the intermediates discussed above matched with those in the literature.
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Scheme 11: Synthesis of aldehyde intermediate 10.
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After completion of the aldehyde synthesis, the next series of reactions highlighted in
Scheme 12 involved the construction of the pyranone ring. This was initiated by a coupling
reaction between the commercially available racemic alkyne 53, and the aldehyde intermediate
10.23 This coupling reaction was achieved using n-BuLi as a base in the presence of dry THF as
solvent. Initial attempts of the coupling reaction provided a very low yield because of the
presence of the tertiary alcohol group on the alkyne and the hydroxyl group of the anthraquinone
ring, both of which are very acidic and will react with the n-BuLi, yielding side products. To
improve the yield, the coupling reaction was run with two equivalents of the alkyne. One
equivalent was used to form a Li+ salt from the hydroxyl group, and one was used to attack the
carbonyl group. This reaction provided the alkynol intermediate 54 with a 53% yield. The
hydroxyl group of intermediate 54 was oxidized to a carbonyl group using MnO2 to provide a
ketone24 which was successfully converted to the pyranone ring by a cyclization reaction using
Cs2CO3 in the presence of DMF to provide intermediate 56 with a 67% yield.25 Intermideiate 56
is present as a racemic mixture because the commercially available alkyne 53 is a racemic
mixture. Intermediate 56 also has an allylic alcohol, and the first attempt to resolve this allylic
alcohol was to use the Sharpless asymmetric epoxidation reaction, which has been successfully
used to resolve racemic allylic alcohols.26,27, 28 After numerous attempts to achieve the kinetic
resolution under the Sharpless conditions, no resolved product was obtained.
The reason for the failure of this reaction was initially attributed to the insolubility of the
intermediate 56. This was not very soluble in DCM. This, coupled to the fact that SAE reactions
are ran at very low temperatures ranging from 0 oC to -20 oC, proved to be very problematic.26
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Scheme 12: First attempt towards the asymmetric synthesis of hydramycin congener 17.
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B. Synthesis of a model compound to test the Sharpless asymmetric
epoxidation reaction.
Due to the difficulties experienced with the SAE reaction, a model compound was
designed and synthesized in order to try the SAE reaction. This model compound synthesized
was 2-phenylbut-3-en-2-ol (63). This molecule was used to try the SAE because it has a
tertiary allylic alcohol possessing a chiral center, which is similar to intermediate 56. The
advantage of using this model compound over intermediate 56 to try the SAE is because of
its solubility properties. This model compound 63 exists physically as an oil and is very
soluble in CH2Cl2. This will therefore be used to ascertain if the failure of the SAE on
intermediate 56 was due to the insolubility of this compound in CH2Cl2. Also, it is easily
obtained in a one-step synthesis that involves the coupling reaction of vinyl magnesium
bromide to benzophenone in the presence of THF as solvent (Scheme 13).29

Scheme 13: Synthesis of model compound 63

After numerous attempts of the SAE reaction on the model compound 63 (Scheme 14), no
successful results were obtained.
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Scheme 14: SAE reaction on the model compound 63.

C. Synthesis of second model compound to test the SAE reaction
Due to the inability to resolve the first model compound synthesized using the SAE, a
second model compound was designed and synthesized. The model compound synthesized was
1-phenylprop-2-en-1-ol (58). This molecule possesses a secondary allylic alcohol and also has a
chiral center. Compound 58 is synthesized as a racemic mixture by the coupling reaction
between vinyl magnesium bromide and benzaldehyde in the presence of THF as solvent (Scheme
15).29 This compound was synthesized to test the SAE in order to be able to ascertain if the
failure of the SAE in the previous reactions was due to the fact that the substrates 56 and 63
being reacted were tertiary allylic alcohols. Compound 58 was then subjected to the conditions
of the SAE. This involved reacting the model compound 58 with Ti(i-PrO)4 in the presence of LDET or D-DET as the ligand and TBHP as the oxidant at 0 oC (Scheme 16).26,30 After
approximately 6 7 h of reaction, the resolved epoxide 59 was obtained with a 49% yield and a
91% de as determined by NMR. The success achieved with the resolution of the compound 58
proved that the resolution of racemic allylic alcohols using SAE is only specific to secondary
allylic alcohols and not to tertiary allylic alcohols.
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Scheme 15: Synthesis of model compound 58.

Scheme 16: Sharpless asymmetric epoxidation on compound 58.
This could be explained by the fact that in the SAE reaction transition state, a complex is
formed between the Ti(i-PrO)4, DET and the OH functional group from the allylic alcohol as
shown in Figure 20 below.

R = i-Pr. R1-3 = H, alkyl, aryl. E = CO2Et

Figure 20: Putative transition state of the SAE reaction.
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We could deduce from this proposed transition-state structure that the more sterically
hindered the allylic alcohol is, the lower the possibility of success of the SAE reaction because
the OH will not be available to complex with the Ti(i-OPr)4 and the DET. This could be used to
explain why tertiary allylic alcohols are not good substrates for SAE. Also, after searching the
literature on different SAE procedures and the different substrates in which they could react,
only one reference could be found in which the SAE was used on a tertiary allylic alcohol to
obtain an enantiomerically pure epoxide. This reaction involved subjecting the tertiary allylic
alcohol (E)-2,5-dihydroxy-2,5-dimethyl-3-hexene to the SAE conditions. After 3.5 days of
reaction, the epoxide was obtained with a very high yield and 70% ee.31 From this paper, we
could conclude that the fact that the reaction is very slow, coupled with the low ee, further
confirms that the sterically crowded tertiary alcohol is not a suitable substrate for the SAE
reaction.
The use of a chiral complex of vanadium, which has been applied for the kinetic resolution
of secondary allylic alcohols,32 was attempted on the tertiary allylic alcohol intermediate 56. This
involved reacting the intermediate 56 with VO(i-PrO)3 and a bishydroxamic acid derivative as
the ligand in the presence of 70% TBHP as oxidant at 0 oC.32 Still, after several trials of this
reaction in which the temperature and concentration of the reactants were varied, no resolved
product was observed.
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D. Synthesis of asymmetric tertiary epoxy alcohols using the Cram-chelate
rule
Because of the inability of the tertiary allylic alcohol to be resolved by the SAE reaction,
a different approach was investigated to synthesize the asymmetric tertiary epoxy alcohol. This
involved using the Cram-chelate rule to synthesize the asymmetric tertiary alcohol 61 and then
try to apply the same reactions to obtain the asymmetric congener 17A. This approach involved
using the Cram-chelate rule to asymmetrically add a Grignard reagent to an asymmetric epoxy
ketone.33-35 The first step in the synthesis of this asymmetric tertiary alcohol compound involved
the SAE reaction on racemic allylic alcohol 58 to obtain the asymmetric epoxy alcohol alcohol
59 as shown in Scheme 16, above. This was followed by an allylic oxidation reaction in the
presence of MnO2 to provide the chiral epoxyketone 60.36 The last step in the synthesis of this
model asymmetric compound 61 was the addition of methylmagnesium bromide to the chiral
epoxyketone. This provided the chiral tertiary epoxy alcohol 62 in very high diastereoselectivity
due to the application of the Cram-chelate addition methodology (Scheme 17).34,37
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Scheme 17: Synthesis of enantiomerically enriched tertiary epoxy alcohol by using the SAE and
the Cram-chelate addition method.

As shown in Figure 21, below, the coordination of the Mg to both the ketone oxygen and
the epoxide oxygen in a pseudo-chair transition state leaves one face of the ketone open to attack
by the Grignard reagent. This therefore leads to an enantiomerically enriched tertiary epoxy
alcohol.

Figure 21: Putative transition state for the addition of MeMgBr to a chiral epoxyketone.
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E. Second attempt to synthesize asymmetric hydramycin congener 17
After successfully obtaining the asymmetric tertiary epoxy alcohol 61 by the Cramchelation addition, the next step was to try to apply this same methodology to the anthraquinone
system in order to obtain the asymmetric version of hydramyin congener 17. The strategy
involved synthesizing an intermediate of the anthraquinone compound with a secondary allylic
alcohol, resolve this intermediate by using the SAE followed by an oxidation, and finally
applying the Cram-chelation addition to get the asymmetric tertiary epoxy alcohol.
The initial steps involved synthesizing the secondary allylic alcohol, because unlike the
tertiary allylic alcohol which is commercially available, the secondary allylic alcohol is not.
Commercially available acrylaldehyde was coupled to TMS acetylene in the presence of n-BuLi
at -78 oC to provide the secondary allylic alcohol 32 in quantitative yield.38,39 The next step
involved protecting the hydroxyl group, and this was efficiently done by reacting allylic alcohol
32 with TBSCl using imidazole as base in the presence of a catalytic amount of DMAP.38,39 This
provided the TBS-protected alcohol 33. Treatment of intermediate 33 with catalytic amount of
K2CO3 in MeOH provided intermediate 3440 (Scheme 18). The NMR spectra of these
intermediates were consistent with those in the literature.38,39
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Scheme 18: Synthesis of protected secondary allylic alcohol 34.

After synthesizing the alkyne intermediate 34, the aldehyde intermediate 10 was also
synthesized using Scheme 11 as earlier described. The next step involved the coupling reaction
between the alkyne intermediate 34 and the aldehyde intermediate 10 in the presence of one
equivalent of n-BuLi to provide intermediate 35. The yield of this reaction was substantially
better than the previous coupling reaction with the tertiary allylic alcohol, because in this case
the alcohol was protected with a TBS group that minimized any possible side products. In order
to synthesize the pyranone ring, the next step involved an allylic oxidation reaction in the
presence of MnO2. The allylic oxidation reaction seemed to be generating the product when
monitored with the Accu-TOF-DART-MS. But after work-up, the oxidized product seemed to
be very unstable and degraded easily. Different oxidation techniques such as the Swern oxidation
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and the use of PCC were employed with no favorable results. Due to the inability to generate a
stable oxidized product, all attempts to synthesize the pyranone ring containing the secondary
allylic alcohol had failed, and we had to seek alternative solutions to synthesize the asymmetric
hydramycin congener 17.

Scheme 19: Attempt to synthesize the anthraquinone compound possessing the secondary allylic
alcohol.
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F. Attempts of enantioselective coupling reaction between the alkyne
containing the tertiary allylic alcohol and the aldehyde intermediate.
Two other methods were employed in order to resolve the racemic tertiary allylic alcohol
intermediate. This involved the enantioselective addition reaction of the alkyne intermediate
containing the tertiary allylic alcohol 53 to the aldehyde intermediate 10 using a variety of chiral
ligands.41,42
The first method involved the ligand-accelerated indium(III)-catalyzed asymmetric
alkynylation of aldehydes with an alkyne containing tertiary alcohols.43 This reaction involved
the coupling reaction between the alkyne intermediate 53 and the aldehyde intermediate 10. This
reaction was attempted with InBr3 as catalyst and (S)-BINOL as the chiral ligand in the presence
of an amine base (Scheme 20). The purpose of this reaction was to generate an asymmetric
center at the C-atom that initially contained the aldehyde functional group which would then
provide a pair of separable diastereomers. Thus such a process would enable one to resolve the
tertiary allylic alcohol and provide enantiomerically pure alkynol intermediates that would be
used to furnish the asymmetric hydramycin congener 17. But after various attempts of this
coupling reaction, no product could be generated.
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Scheme 20: First attempt of enantioselective addition reaction between alkyne and intermediate.

The second attempt of the enantioselective coupling reaction between the aldehyde 10
and the alkyne containing the tertiary allylic alcohol 53 was done in the presence of submolecular equivalent amounts (often termed a catalytic amount) of Zn(OTf)2,

) or

)-N-

ethylephedrine and Et3N.44 The advantage of this enantioselective coupling reaction over the
first method is that it is a truly catalytic system, which implies that all reagents used for this
reaction are in very small amounts. This reaction was attempted with 10 mol% of Zn(OTf)2, 5
mol% of (+)-N-ephedrine as the chiral ligand and 10 mol% of triethylamine as the base (Scheme
21). Also, after several attempts of this reaction at different temperatures, no results could be
obtained from this reaction.
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Scheme 21: Second attempt of enantioselective addition reaction between the alkyne and
intermediate.
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G. Attempts to synthesize the asymmetric version of hydramycin congener
17 using the Sharpless asymmetric dihydroxylation technique.
After various attempts to synthesize the asymmetric version of hydramycin congener 17
using the different asymmetric techniques discussed in the previous section, no apparent results
could be obtained. There was need to explore a different approach in order to synthesize this
compound. The next technique investigated was the Sharpless asymmetric dihydroxylation
(SAD) reaction which is an asymmetric dihydroxylation reaction of olefins with osmium
tetroxide in the presence of dihydroquinine acetate, a chiral tertiary amine ligand that belongs to
the family of Chinchona alkaloids.45 There are various advantages of the SAD over the SAE.
While the SAE reaction requires the presence of a directing functional group in the substrate
(allylic alcohols), the dihydroxylation process is much less limited in the choice of substrate
since it does not need any directing functional group to be present.46 Also, the reagents for the
SAE are not very stable and will dissociate at room temperature. They can therefore not be sold
as a preformulated mixture unlike the SAD reagents, which are solids and are commercially
available as preformulated mixtures because they are very stable at room temperatures.47 The
reagents used for SAD are either AD-mix-α or AD-mix-β that are made up of the necessary
bidentate chiral ligand ((DHQ)2PHAL for AD-mix-α and DHQD)2PHAL for AD-mix-β Figure
22 and 23, respectively)), the stoichiometric oxidant K3Fe(CN)6, and osmium tetroxide in the
form of dipotassium osmate dihydrate (K2OsO4(OH)4).
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Figure 22: Structure of (DHQ)2PHAL (in AD-mix-α)

Figure 23: Structure of (DHQD)2PHAL (in AD-mix-β)

Various mechanistic pathways have been postulated in order to ascertain which route is
followed during the SAD reaction. Studies were performed to be able to determine if the
mechanism of addition of the alkene to the OsO4 proceeds via a [2+2] cycloaddition or a [3+2]
cycloaddition.48 After some kinetic isotope effect studies, it was proven that the most
predominant mechanism in the SAD reaction was the [3+2] cycloaddition as demonstrated in
Scheme 22.49 This mechanism begins with the formation of the osmium tetroxide ligand
complex 2. A [3+2] cycloaddition with the alkene 3 gives the cyclic intermediate 4.48,49 Basic
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hydrolysis liberates the asymmetric diol 5 and the reduced osmate 6. Finally, the stoichiometric
oxidant 7 regenerates the osmium tetroxide ligand complex 2.

Scheme 22: Mechanism of the SAD reaction via the [3+2] cycloaddition pathway.
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1. First attempt for the synthesis of asymmetric hydrymacin congener 17A
and 17A’ via the SAD route.
The strategy in this scheme would entail the synthesis of an asymmetric aldehyde that
will be used as an electrophile and therefore be converted to an epoxide by reaction with
dimethylsulfonium methylide, a sulfur ylide.50,51 This aldehyde could be obtained from a SAD
reaction on intermediate 40 followed by an oxidation reaction. The starting materials for this
scheme are 2-methylbut-3-yn-2-ol (36) and 1-hydroxyanthraquinone (52).

Scheme 23: Retrosynthetic scheme for first attempt of asymmetric hydramycin congener 17 via
SAD route.
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The synthesis of this molecule as highlighted in Scheme 24 below starts with a
dehydration reaction of commercially available 2-methylbut-3-yn-2-ol (36).52,53 This reaction
involves refluxing compound 36 in the presence of concd H2SO4 to provide the enyne 37. The
following step was a coupling reaction with the aldehyde intermediate 10 in the presence of nBuLi to yield the allylic alcohol 38 with a 69% yield. The intermediate 38 was then oxidized
with MnO2 to provide the enynone 39 in quantitative yield. This was followed by the reaction
between the enynone 39 and Cs2CO3 with DMF as solvent to provide the 6-membered pyranone
ring 40 with a 62% yield. The next step in this scheme involved establishing the asymmetric
chiral centers using the SAD reaction. At this step, we were faced with a lot of solubility issues.
Intermediate 40 would not dissolve in any solvent which could be compatible with the SAD
reaction. These solvents are either CH2Cl2, THF, tert-butanol or H2O. The insolubility
experienced with this intermediate 40 was a hindrance to the formation of the diol product, and
only a very insignificant amount of product was formed after seven days of reaction. Due to the
inability to obtain a substantial amount of product from the SAD reaction, this scheme could not
be further exploited to the final compound. However, it was a very useful scheme because it
helped provide an insight into the feasibility of the SAD reaction which would be further
exploited in the next scheme.
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Scheme 24: First attempt for the synthesis of asymmetric hydramycin congener 17 using the
SAD reaction.

44

2. Final attempt for the synthesis of asymmetric hydramycin congener s
17A and 17A’ via the SAD reaction
Due to the versatility of the SAD, the next scheme proposed for the synthesis of the asymmetric
hydramycin congener still took into account the application of the SAD reaction, but this time the
substrate for the SAD will be a trans-1,1,3-trisubstituted olefin which has been proven according to the
literature to provide better yields of the diols and better ee.54 From the retrosynthetic scheme highlighted
in Scheme 25 below, breaking the C–O bond of the epoxide ring will provide the asymmetric diol 16,
which can easily be obtained from the vinyl halide 15. It is very important that the vinyl halide 15 be
exclusively in a trans configuration because the SAD reaction gives better yields and very high ees when
reacting on substituted trans double bonds than with cis double bonds.47 The vinyl halide 15 can easily be
obtained from the TBS-protected allylic alcohol 12 by a deprotection reaction followed by a halogenation
reaction. Intermediate 12 can easily be furnished by a coupling reaction between the alkyne intermediate
6 and the aldehyde intermediate 10 followed by an allylic oxidation. While intermediate 6 can be obtained
through a series of steps from commericially available (E)-crotyl aldehyde (51) involving a stereospecific
dehydrohalogenation reaction to furnish the trans vinyl alcohol, intermediate 10 is easily obtained as
earlier dicussed, from 1-hydroxyanthraquinone (4) in four steps.
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Scheme 25: Retrosynthesis for the final attempt for the asymmetric hydrymacin congener 17A.
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The execution of this synthesis as highlighted in Scheme 26 below was initiated with (E)crotyl aldehyde (51), which is commercially available. The crotyl aldehyde was reduced to (E)crotyl alcohol (1) by Luche reduction using CeCl3 and NaBH4.55,56 Intermediate 1 was converted
to a dibromo alcohol 2 by adding a bromine solution to a solution of intermediate 1 in
CH2Cl2.57,58 With intermediate 2 obtained in quantitative yield, the stage was set to obtain the
vinyl halide 3, which was obtained by a dehydrohalogenation reaction using LDA as the base in
the solvent HMPA.57,58 This reaction furnished exclusively the trans vinyl halide. The NMR
spectra of these intermediates matched with those in the literature.58

Scheme 26: Synthesis of vinyl halide 3.
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Scheme 27 highlighted below shows the incorporation of the alkyne functional group.
This alkyne incorporation was stereospecifically executed by the Sonogoshira cross-coupling
reaction between the vinyl halide 3 and TMS-acetylene using 5 mol% of Pd(PPh3)2Cl2, 20 mol%
of CuI, and DIPEA.58 This process furnished the alkyne intermediate 4 exclusively in the trans
conformation as confirmed by NMR spectroscopy. The next step was the protection of the
primary hydroxyl groups. This was done using TBSCl as the protecting group in the the presence
of imidazole as base and a catalytic amount of DMAP.59,60 This provided intermediate 5 in
quantitative yield. The last step in this scheme involved the removal of the TMS group from the
alkyne in the presence of the O-TBS group using K2CO3 in MeOH.60,61

Scheme 27: Synthesis of alkyne intermediate 6 via Sonogoshira coupling reaction.
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The next series of reactions highlighted in Scheme 28 shows the synthesis of intermediate
15, which is the precursor to the SAD reaction. These next series of reactions start with the
coupling reaction between the alkyne intermediate 6 and the aldehyde intermediate 10 in the
presence of n-BuLi as the base to provide the alkynol intermediate 11. This reaction was
monitored on TLC and quenched after the disappearance of the starting material. It was very
important not to leave the reaction for a very long time because the alkyne intermediate 6, which
is used in excess (2 equivalents) to lithiate the hydroxyl group, could add to the anthraquinone
carbonyls and form byproducts. The next step was an allylic oxidation reaction using MnO2 as
the oxidizing agent to provide the alkynone intermediate 12 in quantitative yield. This was
followed by the cyclization reaction using CsCO3 as the base in the presence of DMF as solvent
to furnish intermediate 13. It was very important for the next series of reactions to follow, that
the acyclic double bond coming off the pyranone ring be in a trans configuration, because that
double bond will be transformed later to an asymmetric diol by the SAD. As initially discussed,
the SAD reaction gives better yields and higher ee’s when reacting on trans double bonds.
NOESY correlations were determined on intermediate 13, and as seen in Figure 23 below, there
was a strong correlation between the CH2 protons and the CH3 protons of the acyclic double
bond. Also, this NOESY experiment helped to determine the conformation of the acyclic double
bond relative to the pyranone ring. From these studies, a strong correlation was observed
between the CH3 group of the double bond and the H atom of the pyranone ring. This therefore
confirms the structure as shown in Figure 24 below. The following step involved the removal of
the TBS protecting group, which was carried out using tetra-n-butylammonium fluoride (TBAF)
to provide the allylic alcohol 14.62 The allylic alcohol was carefully converted to the vinyl halide
15 by initially adding the reagents triethylamine (TEA) and methanesulfonyl chloride (MsCl) to
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form a mesyl ester, which is a good leaving group and using potassium chloride (KCl) as a
source of nucleophile in the presence of 18-crown-6 to displace the mesyl ester intermediate and
provide the vinyl halide 15.63 These steps were preferred to the direct sulfonyl chloride addition
in order to prevent a rearrangement reaction that could lead to a mixture of a tertiary allylic
halide and the primary allylic halide instead of only the desired primary allylic halide.64,65

Figure 24: Intermediate 13 showing NOESY correlations.

50

Scheme 28: Synthesis of intemediate 15 (precurssor to the SAD reaction).

With the intermediate 15 finally obtained, the next step involved the incorporation of the
asymmetric chiral centers, and this was successfully achieved by applying the SAD reaction in
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the presence of AD-mix-β, a catalytic amount of OsO4 and MeSO2NH2 (Scheme 29). This
reaction was run at a low temperature (0 oC), which enhanced the enantioselectivity of the
reaction compared to running the reaction at room temperature.46,66 This asymmetric reaction
provided 80% of the diol intermediate 16. The last step involved a cyclization reaction using
DBU as the base to provide the final coumpound 17A.67,68 The choice of using DBU as the base
for this reaction was due to the non-nucleophilic nature of this base which prevented it from
opening the epoxide ring. Also, the DBU is a bulky base and will selectively attack the proton of
the secondary hydroxyl group over that of the tertiary hydroxyl group.

Scheme 29: Completion of the synthesis of asymmetric hydramycin congener 17A.

As shown in Scheme 30 below, the other enantiomer 17A’ was easily obtained by still applying
the SAD ligand using the reagent AD-mix-α. This successfully installed the asymmetric chiral
center and provided intermediate 18 with the diol group having an opposite stereochemistry to
that of the intermediate 16 above. The last step also involved a cyclization reaction in the
presence of DBU to provide the final enantiomerically pure compound 17A’.
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Scheme 30: Completion of the synthesis of asymmetric hydramycin congener 17A’.
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H. First attempt of the synthesis of two other hydramycin congeners 17B
and 17B’
1. Mitsunobu trial on intermediate 16 or 18.
Having obtained the first pair of enantiomers 17A and 17A’, efforts were now directed
toward the other two pair of enantiomers 17B and 17B’. The inintial attempts involved applying
the Mitsunobu reaction to either of the cis-diol intermediates 16 or 18 in order to invert the
stereochemistry around the secondary hydroxyl group. This was to be followed by the
cyclization reaction to provide the final compound as shown in Scheme 31 below. This reaction
was tried by reacting the diol intermediate 16 with diethylazodicarboxylate (DEAD) in the
presence of PPh3 and using p-nitrobenzoic acid as the nucleophilic source.69 After numerous
attempts of the Mitsunobu reaction on the diol intermediate, no successful results could be
realized. This could be explained by the fact that the nucleophile generated (p-C6H5CO2-) in the
Mitsunobu reaction could be attacking the C atom containing the chloro group instead of the C
atom containing the secondary hydroxyl group hence providing side products. Also, the tertiary
alcohol could be activated to leave, generating a carbocation that leads to epoxide formation.

Scheme 31: First attempt for the synthesis of hydramycin congener 17B via the Mitsunobu
reaction.
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2. Second attempt to synthesize the hydramycin congeners 17B and 17B’ by
applying the Mitsunobu reaction to intermediate 20 and 21
The next approach involved applying the SAD reaction to install the asymmetric chiral
centers on intermediate 13, which provided the diol intermediate 20, and then try to invert the
stereochemistry of the secondary hydroxyl group to obtain a trans-diol using the Mitsunobu
reaction.70,71 The Mitsunobu reaction was monitored using the Accu-TOF-DART-MS, and the
only visible peak on the MS was that of triphenylphosphine oxide (O=PPh3). No visible product
could be observed after MS or TLC analysis. The formation of the triphenylphosphine oxide was
observed immediately after the addition of the reagents, and this could be used to explain why
the reaction did not proceed. The triphenylphosphine is probably reacting with the tertiary
alcohol, which thus makes a good leaving group to form the triphenylphosphine oxide and a
tertiary carbocation is formed as shown in Scheme 32 below.

Scheme 32: Second attempt for the Mitsunobu reaction on intermediate 13 and formation of
triphenylphosphine oxide after the Mitsunobu reaction.
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I. Formation of a trans-diol using the modified irreversible Payne
rearrangement reaction.
At this point it was very clear that success in the synthesis the two other enantiomers 17B
and 17B’ will depend on the development of an efficient method to obtain the trans-diol product
Browsing through the literature, one finds that numerous techniques have been developed to
obtain trans-diols, and one of the methods found in the literature was the formation of an
asymmetric epoxide followed by a regioselective ring opening reaction on the less hindered
epoxide carbon as shown in Scheme 33 below.72,73

R1 = H, alkyl or phenyl.

R2 = H, alkyl or phenyl. Nu = OH

Scheme 33: Opening of asymmetric epoxide to form trans-diols.

However, some limitations were observed with this technique, and one of them was that
the degree of regioselectivity achieved might not be very good. This might lead to a mixture of
different isomers of the trans-diol.73
Due to the limitations of this technique, a different route was explored to obtain the the
trans-diol which will lead to the other two asymmetric hydramycin congeners 17B and 17B’.
This technique is known as the Payne rearrangement, which is the isomerization reaction, under
basic conditions, of 2,3-epoxy alcohols to form isomeric 1,2-epoxy alcohols with inversion of
configuration as shown in the elaborated mechanism in Scheme 34 below.74
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Scheme 34: Mechanism of the Payne rearrangement

As observed in the mechanism elaborated above, the Payne rearrangement reaction is a
reversible process, and during this reaction the equilibrium will lie in the direction of the more
highly substituted epoxide (more stable).74 Because of the reversible nature of the Payne
rearrangement process, which could lead to very low yields of the required product, it has been
exploited to its full synthetic potential by being associated with a regioselective, in situ
nucleophilic trapping in a process called the Payne rearrangement trapping reaction as shown in
Scheme 35 below.75,76 In this mechanism, the more stable substituted 2,3-epoxy alcohol is
converted to the less stable 1,2-epoxy alcohol. In order to push the equilibrium to the right, a
bulky nucleophile is used to attack the less substituted epoxy C-1 to provide the trans diol, which
can then be converted to an epoxide.

Scheme 35: Payne rearrangement reaction followed by nucleophilic trapping.

Efforts were now directed to use the Payne rearrangement to try to obtain the trans diol,
but this will require obtaining an asymmetric epoxide from the allylic alcohol intermediate 14,
which will be the precursor to the Payne rearrangement reaction as described above. The low
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solubility of the allylic alcohol intermediate 14 in CH2Cl2 was a stumbling block to the formation
of the asymmetric epoxy alcohol and therefore the Payne rearrangement technique could not be
further explored.

Scheme 36: SAE trial on intermediate 14

Another method still derived from the Payne rearrangement was explored to obtain the
trans diol which will lead us to the asymmetric hydramycin congeners 17B and 17B’. This
method as shown in the scheme 37 below involved forming a cyclic sulfate from a cis-diol
followed by an intra-molecular nucleophilic opening of the cyclic sulfate intermediate to provide
the epoxide with the C-2 chiral center epimerized.77 Regioselective opening of the epoxide on
the less hindered C-1, followed by the removal of the sulfate group using a catalytic amount of
sulfuric acid to provide the trans-diol in quantitative yield.
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Scheme 37: Formation of trans-diols using the modified irreversible Payne rearrangement
technique.
Also, the nucleophilic opening of the cyclic sulfate could be done intermolecularly followed by
the removal of the sulfate group to provide the trans-diol.78 It should be noted that the cyclic
sulfates have been said to be “like epoxides only more reactive,” and this should therefore be the
driving force to make this reaction feasible.79
The advantage of this method over the classical Payne rearrangement method to obtain
diols is that this method is an irreversible process as compared to the reversible Payne
rearrangement reaction in which the product yield is entirely dependent of the direction in which
the equilibrium lies.80,81 Another advantage of this method over the Payne reaction is that this
reaction is performed in organic solvents such as THF, while the Payne rearrangement is
performed only in aqueous alkaline solutions and could be problematic for most solid organic
compounds.80
Due to the numerous virtues of the modified reversible Payne rearrangement reaction
highlighted above, we then decided to apply this elegant technique to synthesize the other two
hydramycin congeners 17B and 17B’. The formation of the cyclic sulfate as highlighted in
Scheme 38 below was initiated by the SAD reaction on intermediate 13 using AD-mix-β to
obtain the asymmetric diol product 20. The next step involved the formation of the cyclic sulfite
intermediate 21, by reaction of the diol 20 with thionyl chloride at 0 oC in with TEA as the base.
This reaction furnished the cyclic sulfite intermediate 21 after 1.5 h of reaction. This reaction
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was followed by an oxidation reaction in the presence of Ruthenium trichloride-trihydrate and
sodium periodate, to convert the cyclic sulfite intermediate 21 to the cyclic sulfate intermediate
22.81

Scheme 38: Synthesis of the cyclic sulfate intermediate 23.
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Having synthesized the asymmetric cyclic sulfate intermediate 23, the next series of
reactions highlighted in Scheme 39 below shows the route to the final compound 17B. Upon
deprotection of the TBS group from the cyclic sulfate intermediate 23 using TBAF, the
rearrangement took place in situ to provide the intermediate 24 as judged by MS and TLC in
which only base-line material was observed. At this point the desired epimerization around C-2
had been performed, and in order to obtain the final compound 17B, the sulfate group had to be
removed. Unfortunately, the only condition found in the literature to get rid of the sulfate group
was by using concd H2SO4. Under acidic conditions the epoxide ring will be destroyed. In order
to circumvent this issue, the epoxide intermediate 24 generated in situ was reacted with a
saturated solution of sodium iodide for 2 h, which led to a regioselective opening of the epoxide
on the least hindered C atom of the epoxide. At this point, no acid-labile group was present in the
molecule, and the trans-diol intermediate 25 was then finally obtained by the hydrolysis of the
sulfate group using a catalytic amount of H2SO4. It is important to note that the three-step
sequence from the cyclic sulfate intermediate 23 to the trans-diol intermediate 25 was performed
in a single reaction flask without purification of the intermediates and this three-step process
resulted in an overall yield of 60%. The final compound 17B was then easily obtained using
DBU as the base to perform the cyclization reaction.
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Scheme 39: Completion of the synthesis of asymmetric hydramycin congener 17B
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Similarly, the enantiomer of 17B’ was obtained using the same modified irreversible
Payne rearrangement technique. The only difference in the process was the reaction to form the
asymmetric diol. In this reaction, AD-mix-α was used to install the asymmetric chiral centers in a
syn fashion to obtain the diol intermediate 21, which has an opposite stereochemistry from diol
intermediate 22 obtained from AD-mix-β. Following the same steps which lead to the
asymmetric congener 17B highlighted above, we then obtained the hydramycin congener 17B’,
which concluded the total synthesis of all four stereoisomers of the hydramycin congener 17.
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Scheme 39: Completion of the synthesis of hydramycin congener 17B’
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J. Analysis of final compounds and some asymmetric intermediates with
1D and 2D NMR spectroscopy, and chiral column HPLC.
Diol intermediate 16 obtained from AD-mix-β and diol intermediate 18 obtained from
AD-mix-α were analysed by the analytical HP C method using chiralcel AD and the solvent
system 1:1 hexane EtOH. Intermediate 16 had a retention time of 13.4 min while intermediate
18 had a retention time of 7.7 min. The area under each peak was integrated and used to
determine the ee of both intermediates. Intermediate 16 had an ee of 93.4 while intermediate 18
had an ee of 96.4. The optical rotation values were also determined to be -21.1o for intermediate
16 and +19.2o for intermediate 18. Also, some 2D experiments were performed on these
intermediates, and the results of these experiments are summarized in Table 2 below. HSQC
spectra were used to identify the protons attached to the carbons, and we could observe that the
C-1 is attached to two hydrogens which are the Ha and Hb. Other CH groups were also
determined using HSQC. The COSY spectrum was further used to confirm the position of the
adjacent protons. Strong correlations were observed between the adjacent protons Ha, Hb and Hc
as shown in Table 2. NOESY correlations were used to determine the stereochemistry of the
asymmetric centers of these intermediates. The intermediates showed a very strong correlation
between the protons Hb and Hc, and a weak correlation between Hc and Ha. These correlations
and many other correlations as shown in Table 2 strongly support the stereochemistry of the
structures 16 and 18 as shown below. This stereochemistry assigned for the intermediates 16 and
18 will be used as a basis to determine the stereochemistry of the final compounds 17A and
17A’.
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SELECTED 2D NMR CORRELATIONS
NOESY Correlations
H (ppm)
H (ppm)
Hc 4.45
Hd 1.75
Hc 4.45
Hb 4.00 / Ha 3.80
Hb 4.00
Ha 3.80 (v.strong)
Hd 1.75
He 6.80
Hd 1.75
Ha 3.80 (v. weak)
Hd 1.75
Hb 4.00/Hc 4.45
(strong)

HSQC Correlations
H (ppm)
C (ppm)
Hd 1.75
C-4 23.80
Ha 3.80
C-1 45.78
Ha 3.80
C-1 45.78
Hc 4.45
C-2 75.40

COSY Correlations
H (ppm)
H (ppm)
Hc 4.45
Ha 3.80
Hc 4.45
Hb 4.00
Hb 4.00
Ha 3.80

Table 2: 2D NMR correlations for intermediates 16 and 18.
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The optical rotation of intermediate 20 was determined to be -9.4o, while that of
intermediate 21 was +11.7o. The HSQC experiments helped to determine the different methyl,
methylene and methine protons. The Ha and Hb protons are attached to C-1 while the Hc proton is
attached to C-2 as shown in Table 3. From the COSY spectrum, we could observe strong
correlations between the protons Ha, Hb and Hc. This therefore confirms that the three protons
are adjacent to one another. Some long-range correlations could also be observed between the Hf
and Hg protons from the OH groups and the Hd and Hb/Ha respectively. The stereochemistry
around the chiral centers was established using the NOESY correlations, together with the
stereochemistry established from the intermediate 16 and 18 previously discussed. Most
importantly in this correlation was the strong correlation between the OH proton Hg and the Ha
proton, and a weak correlation between the Hg proton and the Hb proton. The NOESY
correlations between the above-mentioned protons were used to determine the stereochemistry of
these intermediates.
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SELECTED 2D NMR CORRELATIONS
NOESY Correlations
H (ppm) H (ppm)
Hd 1.75 Hf 4.50 / Hg 4.43
Hb 3.73 Hc 4.09 / Ha 4.12
Hg 4.43
Hb 3.73 (weak)
Hg 4.43 Ha 4.12 (V. strong)
Hd 1.75 He 6.86

HSQC Correlations
H (ppm)
C (ppm)
Hd 1.75
C-4 24.98
Hb 3.73
C-1 65.39
Ha 4.12
C-1 65.39
Hc 4.09
C-2 74.50

COSY Correlations
H (ppm) H (ppm)
Hd 1.75 Hf 4.50
Hc 4.09 Hb 3.73 / Ha 4.12
Hb 3.73 Ha 4.12
Hg 4.43 Hb 3.73 / Ha 4.12

Table 3: 2D NMR correlations for intermediate 20 and 21.
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The trans-diol intermediates 25 and 30 were each analyzed by the analytical HP C
method using chiralcel AD and the solvent system 3:2 hexane EtOH. Intermediate 25 had a
retention time of 10.5 min, while intermediate 30 had a retention time of 6.7 min. The ee of each
of the enantiomers was determined by integrating the area under each peak. Intermediate 25 had
an ee of 93.4, while intermediate 30 had an ee of 92.6. Also, some 2D experiments were
performed on these intermediates, and the results of these experiments are summarized in Table
4 below. HSQC spectra were used to identify the protons attached to the carbons, and we could
observe that the C-1 is attached to two hydrogens which are Ha and Hb. Other CH groups were
also determined using HSQC. The COSY spectra were further used to confirm the position of the
adjacent protons. Strong correlations were observed between the adjacent protons Ha, Hb and Hc
as shown in Table 4. NOESY correlations, together with the known stereochemistry from
intermediate 20 and 21, were used to determine the stereochemistry of the asymmetric centers of
these intermediates. The intermediates showed a very strong correlation between the protons Hb
and Hc, and a weak correlation between Hc and Ha. These correlations and many other
correlations as shown in the Table 4 strongly support the stereochemistry of the structures 25 and
30.
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SELECTED 2D NMR CORRELATIONS
NOESY Correlations
H (ppm)
H (ppm)
Ha 3.30
Hb 3.50
Hc 4.28
Ha 3.30
Hc 4.28
Hb 3.50 (v.strong)
Hd 1.79
Hc 4.28 / He 6.73
Hd 1.75
Ha 3.30 / Hb 3.50

HSQC Correlations
H (ppm)
C (ppm)
Ha 3.30
C-1 8.27
Hb 3.50
C-1 8.27
Hd 1.79
C-4 23.64
He 6.73
C-6 109.73

COSY Correlations
H (ppm)
H (ppm)
Hc 4.28
Hb 3.50
Hc 4.28
Ha 3.30
Ha 3.30
Hb 3.50

Table 4: 2D NMR correlations for intermediate 25 and 30.
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The final compounds 17A and 17A’ were analysed with the analytical HP C method
using chiralcel AD and the solvent system 55:45 hexane EtOH. The retention time of the
enantiomer 17A on this column was 11 min while that of enantiomer 17A’ was 9.1 min. The
integration of the areas under each peak was determined in order to obtain the ee. Enantiomer
17A has an ee of 93% while the ee of enantiomer 17A’ is 94%. The optical rotation values
measured further confirmed the chiral nature of these final compounds. Enantiomer 17A has an
optical rotation of +28.6o while 17A’ is -31.2o. The 2D NMR experiments were performed in
order to establish the correct stereochemistry around the chiral centers. The final compounds
17A and 17A’ being enantiomers, had identical NMR spectra. HSQC was initially used to assign
all the methyl, methylene and methine protons as shown in Table 5 below. The COSY spectra
were then used to confirm the presence of the adjacent H atoms Ha, Hb and Hc. Also, a strong
COSY correlation was observed between the adjacent Hd from the CH3 group and He from the
OH group. NOESY and HMBC correlations were used to assign the stereochemistry and also the
conformation of the various groups present. The NOESY correlations among the Hd, He and Hf
protons confirms the proximity of these 3 protons. Also, a strong NOESY correlation was
observed between the the Hd and Hc protons and between Hd and Hb but not with Ha. These
correlations were used together with the known stereochemistry form the chiral intermediate 16
and 18, to deduce the relative stereochemistry for the final compound 17A and 17A’. This
stereochemistry was further confirmed by some HMBC correlations in which we could see some
strong correlations such as those between the C-2 and He, and between C-3 and Hb as highlighted
in Table 5 below.
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SELECTED 2D NMR CORRELATIONS
HMBC
COSY

NOESY
H (ppm)
Ha 2.97
Hb 3.03
He 2.83
Hd 1.77
Hd 1.77
Hd 1.77

H (ppm)
Hc 3.96
Hc 3.96
Hf 6.74
Hc 3.96
Hb 3.03
Hf 6.74

H
He
He
Hd
Hb

(ppm)
2.83
2.83
1.77
3.03

C (ppm)
C-4 23.09
C-2 55.50
C-5 172.57
C-3 70.90

H (ppm)
Hd 1.77
Hc 3.96
Hc 3.96

H (ppm)
He 2.83
Hb 3.03
Ha 2.97

HSQC

C (ppm)
C-1 43.75
C-1 43.75
C-2 55.50
C-4 23.09

Table 5: 2D NMR correlations for final compound 17A and 17A’
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H (ppm)
Ha 2.97
Hb 3.03
Hc 3.96
Hd 1.77

In an identical manner, the final compounds 17B and 17B’ were analyzed with the
analytical HP C method using chiralcel AD and the solvent system 55:45 hexane EtOH. The
retention time of the enantiomer 17B on this chiral column was 8.6 min while that of enantiomer
17B’ was 15.1 min. The integration of the areas under each peak was also determined in order to
obtain the ee. Enantiomer 17B has an ee of 93%, while the ee of enantiomer 17B’ is 95%. The
optical rotation values measured further confirmed the chiral nature of these final compounds.
Enantiomer 17B has an optical rotation of +55.02 while 17B’ is -50.25. The 2D NMR
experiments were performed in order to assign the correct stereochemistry around the chiral
centers. Final compounds 17B and 17B’ being enantiomers, had the same NMR spectra. HSQC
was initially used to assign all the methyl, methylene and methine protons as shown in table 6
below. The COSY spectra were then used to confirm the presence of the adjacent H atoms Ha, Hb
and Hc. Also, a strong COSY correlation was observed between the adjacent Hd from the CH3
group and He from the OH group. NOESY and HMBC correlations were used to assign the
stereochemistry and also the conformation of the various groups present. The NOESY
correlation between the Hd, He and Hf protons confirms the proximity of these three protons as
shown in Table 6. Also, a strong NOESY correlation was observed between the Hd and Hc
protons but not with either Hb or Ha protons. This shows that the Ha and Hb are very far from Hd
as shown in table 6 below. Also, there is no correlation between Hc and He which further
confirms that Hd and Hc are pointing in the same direction. A NOESY correlation was also
observed between Ha and Hf. These correlations were used together with the known
stereochemistry form the chiral intermediate 20 and 21, to deduce the relative stereochemistry
for the final compound 17B and 17B’. This stereochemistry was further confirmed by some
HMBC correlations in which we could see some strong correlations such as those between the C73

2 and He, C-3 and Hb and more distinctly on the HMBC spectra, a strong long range M pattern
could be observed between C-1 and Hd as shown in Table 6 below.

SELECTED 2D NMR CORRELATIONS
HMBC
COSY

NOESY
H (ppm)
Ha 2.93
He 2.65
He 2.65
Hd 1.90
Hd 1.90
Hd 1.90

H (ppm)
Hf 6.71
Hf 6.71
Ha 2.93
Hc 3.77
He 2.65
Hf 6.71

H
Ha
Hb
Hd
Hd
He
He
He

(ppm)
2.80
2.93
1.90
1.90
2.65
2.65
2.65

C (ppm)
C-3 70.77
C-3 70.77
C-1 44.13 (M)
C-2 56.10
C-2 56.10
C-4 25.64
C-5 171.03

H (ppm)
Hd 1.90
Hc 3.77
Hc 3.77

H (ppm)
He 2.65
Hb 2.80
Ha 2.93

HSQC
C (ppm)
C-1 44.13
C-1 44.13
C-2 56.10
C-4 25.64

Table 6: 2D NMR correlations for final compound 17B and 17B’
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H (ppm)
Ha 2.80
Hb 2.93
Hc 3.77
Hd 1.90

Figure 25: 3D modeling for final compound 17A

Figure 26: 3D modeling for final compound 17A’
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Figure 27: 3D modeling of final compound 17B

Figure 28: 3D modeling of final compound 17B’
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V. CONCLUSIONS AND FUTURE WORK
Numerous difficulties were encountered with the asymmetric synthesis of the four
isomers of the hydramycin congener 17. These difficulties ranged from the insolubility of some
intermediates to the incompatibility to some asymmetric processes that are very substrate
specific. Still, it was possible to generate all four enantiomerically pure congeners of hydramycin
17 each having an ee of more than 90%. This was made possible by using the SAD technique
after failed attempts with the SAE reaction. One of the virtues of the SAD technique is its
versatility to accommodate different functional groups. This virtue could therefore be extended
to the design and synthesis of the hydramycin itself as will be discussed below.
The synthetic route used in this dissertation to synthesize the asymmetric versions of the
hydramycin congener 17, could be extended to the asymmetric synthesis of hydramycin itself.
Due to the complicated substitution pattern around the anthraquinone ring, the fully substituted
starting material would have to be synthesized rather than being obtained commercially.
Scheme 41 shows how this can be done, and this will be initiated by reaction of the
commercially available halo quinone and electron-rich diene in the presence of CrO3/AcOH and
toluene as solvent to provide intermediate 6582. The hydroxyl group of the phenol would be
protected with TBS, which can easily be removed in the later stages of the synthesis. This will
provide intermediate 66, which would be converted to the substituted anthraquinone
intermediate 68 by reaction with commercially available methyl 3-methyl-2-butenoate.83,84
Conversion of intermediate 68 to the aldehyde intermediate 69 would be achieved using the
process discussed previously.
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Scheme 41: Future work for the synthesis of anthraquinone intermediate 69 towards the
synthesis of hydramycin.
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Scheme 42 shows how the synthesis of the asymmetric hydramycin compound could be
completed. The alkyne intermediate 72 could be synthesized from the commercially available
starting material but-2-yne-1,4-diol. The but-2-yne-1,4-diol would be converted to the iodo diol
intermediate 70 in the presence of Pd(PPh3)4 and Bu3SnH.85 Intermediate 70 would then be
subjected to Sonogoshira coupling conditions with TMS-acetylene to provide intermediate 71.
The diol of intermediate 71 would be selectively protected with TMS and TBS protecting
groups, respectively. This would be followed by a coupling reaction and an allylic oxidation
reaction to provide intermediate 73. The TMS group would be removed and the resulting
hydroxyl group would be converted to a chloro group to provide intermediate 74. The
asymmetric chiral centers would be introduced at this stage by subjecting intermediate 74 to the
SAD reaction conditions. This would furnish the asymmetric diol intermediate 75 which would
be converted to the final hydramycin compound by the cyclization reaction, followed by the
removal of the TBS protecting groups.
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Scheme 42: Future work for completion of the synthesis of hydramycin.
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V. EXPERIMENTALS
A. General Methods

Analytical TLC was performed on aluminium-backed plates coated with E. Merck silica
gel, and detection was done by irradiating the TLC plate with 254 nm UV light and/or charring
with p-anisaldehyde dip. Column chromatography was run by using silica gel, 63 200 mesh.
Analytical HPLC was performed using the chiral column CHIRALCEL AD. 1H and 13C NMR
spectra were acquired at rt on a Varian Mercury at 300 MHz and 75 MHz, a Varian Mercury at
500 MHz and 125 MHz and Varian Inova 600 MHz and 150 MHz. Chemical shifts were
reported as δ (ppm) values. All 2D NMR experiments (gCOSY, HSQC, HMBC and NOESY)
experiments were acquired on the Varian Inova 600. High resolution mass spectra were
determined on the AccuTOF-DART-MS and the AccuTOF-QStar Elite-MS.
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B. Preparation of tert-Butyldimethyl(pent-1-en-4-yn-3-yloxy)silane (34)
Preparation of 5-(trimethylsilyl)pent-1-en-4-yn-3-ol (32):

Trimethylsilylacetylene (2.0 mL, 14 mmol) was dissolved in dry THF and cooled to -78 oC. To
this solution was added a 2.5M solution of n-BuLi in hexanes(6.16 mL, 15.4 mmol) dropwise.
The reaction was stirred at this temperature for 30 min and acrolein (1.2 mL, 21 mmol) was
added. The reaction was stirred for further 2 h at -78 oC and after complete consumption of the
starting material as indicated on TLC, the reaction was quenched with satd NH4Cl. The organic
phase was washed with brine and dried over MgSO4. This organic phase was then concentrated
and purified by column chromatography using the solvent system 90:10 hexane Et2O as the
mobile phase to give 2.11 g (13.7 mmol, 98%) of the desired product.
1

H NMR (300 MHz, CDCl3): δ 6.01 5.90 m, 1H), 5.49 5.43 d, 1H), 5.23 5.20 (d, 1H), 4.86

(td, 1H), 2.10 (d, 1H), 0.18 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 136.77, 116.20, 104.45,
90.43, 63.01, -0.026. The NMR spectra matched those previously reported.38
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Preparation of tert-Butyldimethyl((5-(trimethylsilyl)pent-1-en-4-yn-3yl)oxy)silane (33):

A solution containing intermediate 32 (1.4 g, 9.1 mmol), imidazole (1.24 g, 18.2 mmol), TBSCl
(2.06 g, 13.6 mmol) and a catalytic amount of DMAP in CH2Cl2 was stirred overnight at rt. The
mixture was quenched with satd NH4Cl and extracted with CH2Cl2, and the organic extracts were
dried over MgSO4. The crude material was purified by column chromatography using the
solvent system 9:1 peroleum ether Et2O to give 2.30 g (8.55 mmol, 94%) of 33 as a colorless oil.
1

H NMR (300 MHz, CDCl3): δ 5.95 5.83 m, 1H), 5.43 5.38 d, 1H), 5.16 5.12 (d, 1H), 4.90(s,

1H), 0.92(s, 9H), 0.17 s, 9H), 0.15 0.14 (d, 1H);

13

C NMR (75 MHz, CDCl3): δ 137.46,

114.74, 105.08, 89.92, 64.03, 25.76, 18.28, -0.26, -4.53, -4.83. The NMR spectra matched those
previously reported.38
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Preparation of tert-Butyldimethyl(pent-1-en-4-yn-3-yloxy)silane (34):

Intermediate 33 (2.30 g, 8.55 mmol) was dissolved in MeOH, and a catalytic amount of K2CO3
was added. The reaction was allowed to stir at rt for 3 h. After complete consumption of the
starting material as revealed on TLC, the reaction was quenched with satd NH4Cl and the organic
phase was extracted with CH2Cl2. This organic extract was dried over MgSO4 and purified via
column chromatography using the solvent system 9:1 petroleum ether Et2O to give 1.6 g (8.12
mmol, 95%) of 34 as a colorless oil.
1

H NMR (300 MHz, CDCl3): δ 5.95 5.85 m, 1H), 5.43 5.38 d, 1H), 5.17 5.13 (d, 1H), 4.89

(s, 1H), 2.48 (d, 1H), 0.92 (s, 9H), 0.15 0.13 (d, 6H);

13

C NMR (75 MHz, CDCl3): δ 137.40,

115.01, 83.36, 73.32, 63.42, 25.65, 18.25, -4.67, -4.96. The NMR spectra matched those
previously reported.38
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C. Synthesis of 2-(4-((tert-Butyldimethylsilyl)oxy)-1-hydroxyhex-5-en-2-yn1-yl)-1-hydroxyanthracene-9,10-dione (35):

Intermediate 34 (0.781 g, 3.97 mmol) was dissolved in dry THF and purged with N2 for 15
min. The temperature of the reaction was reduced to -78 oC and a 2.5 M solution of n-BuLi in
hexanes (1.58 mL, 3.97 mmol) was added dropwise. The reaction mixture was allowed to
slowly warm up to 0 oC for about 3 h. The temperature of the reaction flask was again reduced
to -78 oC and intermediate 10 (0.45 g, 1.8 mmol) dissolved in dry THF was quickly added into
the reaction flask via a syringe. The reaction was quickly warmed up to rt and stirred for 0.5 h.
After complete consumption of the aldehyde as indicated on TLC, the reaction was quenched
with satd NH4Cl. The organic phase was extracted with CH2Cl2, dried over anhyd MgSO4 and
concentrated. Purification of the crude material was achieved with a silica gel column using
the solvent system 6.0:3.6:0.4 hexane CH2Cl2 EtOAc to yield 0.476g (1.06 mmol, 59%) of 11
as a dark-brown oil.
1

H NMR (300 MHz, CDCl3): δ 12.95 s, 1H), 8.10 8.07(d, 1H), 7.90 7.87 d, 1H), 7.69 7.63 m,

3H), 5.96 5.85(m, 1H), 5.82(s, 1H), 5.42-5.36(d, 1H), 5.15-5.12(d, 1H), 4.98(s, 1H), 3.55(s, 1H),
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0.85(s, 9H), 0.08(s, 6H); 13C NMR (75 MHz, CDCl3): 188.51, 181.70, 159.54, 137.30, 135.38,
134.76, 134.54, 134.13, 133.26, 132.74, 132.69, 127.30, 126.77, 119.25, 115.65, 115.23, 86.38,
83.32, 63.70, 59.48, 25.74, 18.27, -4.62, -4.86. The NMR spectra matched those previously
reported.52
HR-AccuTOF-DART-MS: Calcd for C26H28O5Si, m/z 448.17060,; [M-OH]+ m/z 431.16786
(calcd 431.16627).

D. Synthesis of 2-(prop-1-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12trione (40):
Preparation of 2-methylbut-1-en-3-yne (37):

Commercially available starting material 36 (14 g, 0.17 mol) was added into a round bottom
flask followed by 10 mol % of an 18M H2SO4 acid solution. The resulting solution was heated to
70 oC and the product of the dehydration reaction was obtained by distillation into a 25 mL
round bottom flask to provide 7.2 g (0.11 mol, 65%) of 11 as a colorless oil.
1

H NMR (300 MHz, CDCl3): δ 5.32 s, 1H) 5.23 s, 1H), 2.82 s, 1H), 1.84 s, 3H);

MHz, CDCl3): δ 125.87, 123.05, 84.67, 76.11, 22.93
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13

C NMR (75

Synthesis of 1-Hydroxy-2-(1-hydroxy-4-methylpent-4-en-2-yn-1yl)anthracene-9,10-dione (38):

Intermediate 37 (0.33 mL, 3.5 mmol) was dissolved in dry THF and the temperature of the
reaction was reduced to -78 oC. The solution was purged with N2 for 15 min and a 2.5 M
solution of n-BuLi in hexanes (1.40 mL, 3.52 mmol) was added dropwise. The reaction mixture
was allowed to stir for about 45 min and intermediate 10 (0.40 g, 1.6 mmol) dissolved in dry
THF was quickly added into the reaction flask via a syringe. The reaction was quickly warmed
up to rt and stirred for 0.5 h. After complete consumption of the aldehyde as indicated on TLC,
the reaction was quenched with satd NH4Cl. The organic phase was extracted with CH2Cl2, dried
over anhyd MgSO4 and concentrated. Purification of the crude material was achieved with a
silica gel column using the solvent system 4.0:4.0:2.0 hexane CH2Cl2 EtOAc to yield 0.35 g
(1.1 mmol, 69%) of 38 as a dark-brown oil.
1

H NMR (300 MHz, CDCl3): δ 13.04 s, 1H), 8.15 m, 1H), 7.94-7.91 (d, 1H), 7.73(m, 1H), 5.91

(s, 1H), 5.36(s, 1H), 5.27(s, 1H), 3.45(s, 1H), 1.90(s, 3H); 13C NMR (75 MHz, CDCl3): δ 188.65,
181.83, 159.66, 135.45, 134.80, 134.62, 134.17, 133.35, 132.84, 132.81, 127.36, 126.83, 125.96,
123.07, 119.37, 115.78, 88.12, 85.88, 60.01, 23.27.
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HR-AccuTOF-DART-MS: Calcd for C20H14O4, m/z 318.08921, [M-OH]+ m/z 301.08647 (calcd
301.08528 ).

Synthesis of 1-Hydroxy-2-(4-methylpent-4-en-2-ynoyl)anthracene-9,10-dione
(39):

To a solution containing intermediate 38 (0.35 g, 1.1 mmol) in 40 mL of CH2Cl2, was added
MnO2 (1.81 g, 20.7 mmol). The reaction flask was stirred for 3 h, and the mixture was filtered
over celite and concentrated to give 0.30 g (0.95 mmol, 86%) of 12 as a dark-brown oil.
1

H NMR (300 MHz, CDCl3): δ 13.50 s, 1H), 8.22 8.20 (d, 1H), 8.16 8.10 (d, 2H), 7.73 (m, 3H),

5.69(s, 1H), 5.60(s, 1H), 2.00(s, 3H);

13

C NMR (75 MHz, CDCl3): δ 188.02, 181.39, 174.93,

162.70, 139.06, 136.43, 134.98, 134.58, 132.84, 132.80, 129.94, 128.55, 127.32, 127.04, 124.92,
117.96, 117.19, 95.04, 87.11, 22.34.
HR-AccuTOF-DART-MS: Calcd for C20H12O4, m/z 316.07356, [M+H]+ m/z 317.08138 (calcd
317.08174 ).
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Synthesis of 2-(prop-1-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione
(40):

To a solution of intermediate 39 (0.26 g, 0.82 mmol) in dry DMF (20 mL), was added Cs2CO3 (0.29
g, 0.90 mmol). The reaction was stirred at rt for 1 h and quenched with satd NH4Cl. The organic
phase was extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the crude product
was achieved with column chromatography using the solvent system 4.0:4.0:2.0 hexane CH2Cl2
EtOAc to yield 0.14 g (0.51 mmol, 62%) of 40 as a yellow solid.
1

H NMR (300 MHz, CDCl3): δ 8.59 8.58 (d, 1H), 8.33 8.28 m, 3H), 7.86 7.80(m, 2H), 6.86(s,

1H), 6.50(s, 1H), 5.75(s, 1H), 2.16(s, 3H);

13

C NMR (75 MHz, CDCl3): δ 182.21, 181.14, 177.44,

164.74, 154.30, 137.84, 134.92, 134.73, 134.31, 134.01, 132.18, 131.76, 127.85, 127.31, 127.04,
123.73, 122.85, 122.40, 108.49, 18.64.
HR-AccuTOF-DART-MS: Calcd for C20H12O4, m/z 316.07356, [M+H]+ m/z 317.08138 (calcd
317.08193).
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E. Preparation of 2-(2-hydroxybut-3-en-2-yl)-4H-naphtho[2,3-h]chromene4,7,12-trione (55)
Preparation of 2-(1, 4-dihydroxy-4-methylhex-5-en-2-yn-1-yl)-1hydroxyanthracene-9,10-dione (54)

Intermediate 53 (0.283 mL, 2.61 mmol) was dissolved in dry THF and purged with N2 for 15
min. The temperature of the reaction was reduced to -78 oC and a 2.5 M solution of n-BuLi
in hexanes (2.1 mL, 2.9 mmol) was added dropwise. The reaction mixture was allowed to
slowly warm up to 0 oC for about 3 h. The temperature of the reaction flask was again reduced
to -78 oC and intermediate 10 (0.300 g, 1.19 mmol) dissolved in dry THF was quickly added into
the reaction flask via a syringe. The reaction was quickly warmed up to rt and stirred for 0.5 h.
After complete consumption of the aldehyde as indicated on TLC, the reaction was quenched
with satd NH4Cl. The organic phase was extracted with CH2Cl2, dried with anhyd MgSO4 and
concentrated. Purification of the crude material was achieved with a silica gel column using the
solvent system 7:3 hexane EtOAc to yield 0.22 g (0.64 mmol, 53%) of 54 as a dark-brown oil.
1

H NMR (500 MHz, CDCl3): δ 13.22 s, 1H), 8.33 8.29 m, 2H), 7.99 7.96 d, 1H), 7.87 7.81

m, 3H), 6.04 5.96 m, 1H), 5.91 s, 1H), 5.56 5.50 d, 1H), 5.17 5.14 (d, 1H), 1.61(s, 3H); 13C
NMR (125 MHz, CDCl3): δ 189.02, 182.03, 159.97, 141.51, 135.07, 134.95, 134.59, 134.28,
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133.60, 133.16, 133.05, 127.53, 127.00, 119.49, 116.09, 114.08, 89.00, 82.55, 68.31, 60.23,
29.87. The NMR spectra matched those previously reported.21
HR-AccuTOF-DART-MS: Calcd for C21H16O5, m/z 348.09977; [M-OH]+ m/z 331.09703 (calcd
331.09637).

Preparation of 2-(2-hydroxybut-3-en-2-yl)-4H-naphtho[2,3-h]chromene4,7,12-trione (55)

To a solution containing intermediate 54 (0.20 g, 0.57 mmol) in 40 mL of CH2Cl2, was added
MnO2 (1.00 g, 11.5 mmol). The reaction flask was stirred at rt for 4 h, and after complete
consumption of the starting material as monitored on the Accu-TOF-DART-MS, the mixture was
filtered over celite and concentrated to give 0.18 g (0.52 mmol, 91%) of the oxidized product as
a dark-brown oil. The oxidized alkynone was dissolved in dry DMF (20 mL) and Cs2CO3 (0.19
g, 0.57 mmol) was added to the reaction flask. The reaction was stirred at rt for 1.5 h and after
complete consumption of the alkynone intermediate as monitored on TLC, the reaction was
quenched with satd NH4Cl. The organic phase was extracted with CH2Cl2 and dried with anhyd
MgSO4. Purification of the crude product was achieved with column chromatography using the
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solvent system 7:3 hexane EtOAc to yield 0.12g (0.35mmol, 67%) of 55 as a yellow solid
product.
1

H NMR (300 MHz, CDCl3): δ 8.62 8.60 d, 1H), 8.38 8.30 m, 3H), 7.89 7.81 m, 2H), 6.64 s,

1H), 6.39 6.29 m, 1H), 5.62 5.56 (d, 1H), 5.36 5.33(d, 1H), 1.84(s, 3H);

13

C NMR (75 MHz,

CDCl3): δ 182.20, 181.20, 177.00, 172.41, 154.26, 140.31, 137.69, 134.79, 134.20, 134.17,
132.22, 131.92, 127.87, 127.37, 127.16, 123.16, 115.32, 107.66, 74.07, 26.59. The NMR spectra
matched those previously reported.21
HR-AccuTOF-DART-MS: Calcd for C21H14O5, m/z 346.08412; [M+H]+ m/z 347.09140 (calcd
347.09289).

F. Preparation of 2-phenylbut-3-en-2-ol (63)

To an oven-dried round bottom flask was added acetophenone 62 (1.17 mL, 10 mmol) in THF
(10 mL) and purged with N2 for 15 min. The temperature of the flask was reduced to 0 oC and a
1.0 M vinyl magnesium bromide solution in THF (12 mL, 12 mmol) was added to the flask and
stirred for 30 min at 0 oC. The reaction was warmed up to rt and stirred for an additional 3 h.
After complete consumption of the starting material as indicated on TLC, the reaction was
quenched with satd NH4Cl. The organic phase was extracted with CH2Cl2 and dried with anhyd
MgSO4. Purification of the crude product was achieved with column chromatography using the
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CH2Cl2 as the only solvent to yield 1.40 g (9.47 mmol, 94.7%) of 58 as a clear oil.
1

H NMR (300 MHz, CDCl3): δ 7.54 7.51 m, 2H), 7.40 7.28 (m, 3H), 6.25 6.16 d, 1H), 5.36

5.30 d, 1H), 5.19 5.15 (d, 1H), 2.67 (s, 1H), 1.68 (s, 3H).;

13

C NMR (75 MHz, CDCl3): δ

166.15, 146.61, 144.98, 128.25, 126.98, 125.35, 112.37, 74.83, 29.33.
HR-AccuTOF-DART-MS: Calcd for C10H12O, m/z 148.08882; [M-OH]+ m/z 131.08553 (calcd
131.08341).

G. (S)-1-((S)-oxiran-2-yl)-1-phenylethanol (61)
Preparation of 1-phenylprop-2-en-1-ol (58)

To an oven-dried round bottom flask was added benzaldehyde 57 (1.25 mL, 11.8 mmol) in THF
(10 mL) and purged with N2 for 15 min. The temperature of the flask was reduced to 0 oC and
the vinyl magnesium bromide (14.16 mL, 14.16 mmol) was added to the flask and stirred for 30
min at 0 oC. The reaction was warmed up to rt and quenched with satd NH4Cl. The organic phase
was extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the crude product was
achieved with column chromatography using the solvent system 7:3 hexane Et2O to yield 1.5 g
(11.2 mmol, 94.7%) of 58 as a clear oil.
1

H NMR (300 MHz, CDCl3): δ 7.40 m, 5H), 6.07 m, 1H), 5.39 5.33 (d, 1H), 5.24 5.21 d,

1H), 5.17 5.15 (d, 1H), 3.44 (br s, 1H); 13C NMR (75 MHz, CDCl3): δ 142.45, 140.06, 128.17,
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127.29, 126.17, 114.69, 74.82.
HR-AccuTOF-DART-MS: Calcd for C10H12O, m/z 134.07316; [M-OH]+ m/z 117.07043 (calcd
117.06603).

Synthesis of (R)-((S)-oxiran-2-yl)(phenyl)methanol (59)

To a dried 100 mL round bottom flask was added 4Ao molecular sieves and 5 mL of DCM. To
this suspension was added L-DET (0.08 mL, 0.46 mmol) and the racemic intermediate 58 (1.00
g, 7.45 mmol). The mixture was cooled to -5 oC and Ti(iOPr)4 (0.09 mL, 0.30 mmol) was added.
The reaction was stirred for 30 min and then TBHP (1.35 mL, 7.45 mmol) was added dropwise
within 30 min. The reaction was warmed up to 0 oC and stirred for 7 h and the reaction was
quenched by adding a satd solution of ferric sulfate and citric acid. The organic phase was
extracted with DCM, washed with brine and dried with anhyd MgSO4. Purification of the crude
material was achieved using the solvent system 6:4 hexane Et2O to yield 0.55 g (3.6 mmol, 49
%) of 59 as a clear oil.
1

H NMR (300 MHz, CDCl3): δ 7.37 m, 5H), 4.83 d, 1H), 3.19 m, 1H), 2.92 dd, 1H), 2.73 (dd,

1H);

13

C NMR (75 MHz, CDCl3): δ 139.44, 128.38, 128.02, 126.27, 70.75, 55.01, 43.57.

HR-AccuTOF-DART-MS: Calcd for C9H10O2, m/z 150.06808; [M+H]+ m/z 151.07590 (calcd
151.07656)
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Synthesis of (S)-oxiran-2-yl(phenyl)methanone (60)

To a solution containing intermediate 59 (0.330 g, 2.19 mmol) in 40 mL of CH2Cl2, was added
MnO2 (9.00 g, 103 mmol). The reaction flask was stirred at rt for 24 h, and after complete
consumption of the starting material, the mixture was filtered over celite and concentrated. The
crude material was purified by column chromatography using the solvent system 6:4 hexane
Et2O to yield 0.25 g (1.7 mmol, 78 %) of 60 as a white crystal solid.
1

H NMR (300 MHz, CDCl3): δ 8.00 7.97 d, 2H), 7.58 t, 1H), 7.45 t, 2H), 4.22 4.19 m, 1H),

3.09 3.05 (dd, 1H), 2.92 2.89 (dd, 1H); 13C NMR (75 MHz, CDCl3): δ 194.47, 135.18, 133.76,
128.63, 128.09, 50.83, 47.42.
HR-AccuTOF-DART-MS: Calcd for C9H8O2, m/z 148.05243; [M+H]+ m/z 149.06025 (calcd
149.05933).
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Synthesis of (S)-1-((S)-oxiran-2-yl)-1-phenylethanol (61)

A solution of intermediate 60 (0.180g, 1.21 mmol) was dissolved in dry THF and the
temperature of the solution was reduced to -78 oC. To this solution was added MeMgBr (0.806
mL, 2.42 mmol) dropwise. The reaction was ran for 3 h at this temperature and after complete
consumption of the starting material, the reaction was quenched with satd NH4Cl. The organic
phase was washed with brine, dried with anhyd MgSO4 and concentrated. Purification of the
crude material was achieved with a silica gel column using the solvent system 9:1 hexane Et2O
to yield 0.19 g (1.16 mmol, 96%) of 61 as a clear oil.
1

H NMR (300 MHz, CDCl3): δ 7.50 7.48 d, 2H), 7.41 7.26 m, 3H), 3.22 3.20 dd, 1H), 2.90

2.88 dd, 1H), 2.71 2.68 (dd, 1H), 2.23 (br s, 1H), 1.70 (s, 3H);

13

C NMR (75 MHz, CDCl3): δ

143.49, 128.37, 127.43, 124.96, 70.65, 58.67, 44.41, 27.88.
HR-AccuTOF-DART-MS: Calcd for C10H12O2, m/z 164.08373; [M+H]+ m/z 165.09155 (calcd
165.09130).
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H. Preparation of (E)-3-Methyl-5-(trimethylsilyl)pent-2-en-4-yn-1-ol (4)
Preparation of (E)-But-2-en-1-ol (1)

To a stirred solution of (E)-crotyl aldehyde (5.00 mL, 60.4 mmol) in MeOH was added CeCl3
(5.00 g, 20.3 mmol). After 10 min, the mixture was cooled to 0 oC and NaBH4 (2.51 g, 66.4
mmol) was added. The reaction mixture was stirred at 0 oC until total consumption of starting
material (1 h) was achieved. The reaction was quenched by adding a satd solution of NH4Cl.
CH2Cl2 was subsequently added, and the heterogenous mixture was extracted with CH2Cl2. The
organic layer was washed with brine and dried over MgSO4. The solvent was evaporated in
vacuo, and purification was achieved using column chromatography with the solvent system
60:40 hexane EtOAc to provide 4.13 g (95%, 57.3 mmol) of pure (E)-but-2-en-1-ol as a clear
oil.
1

H NMR (300 MHz, CDCl3): δ 5.47 m, 1H), 5.45 m, 1H), 3.97 br s, 1H), 3.82

1.52 (d, 3H);

13

d, 2H), 1.53

C NMR (75 MHz, CDCl3): δ 130.20, 127.02, 62.73, and 17.34. The 1H and 13C

NMR data matched those previously reported.86
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Preparation of 2,3-Dibromobutan-1-ol (2).57,58

To a solution of 1 (4.00 mL, 46.9 mmol) dissolved in 20 mL of CH2Cl2 at -78 oC, was added
liquid Br2 dropwise until the orange color from bromine persisted. The reaction was warmed up
to rt, stirred for 1.5 h and quenched with satd Na2S2O3. The organic layer was washed with
brine, dried with MgSO4, concentrated and then purified by column chromatography using
CH2Cl2 as the mobile phase to give 9.90 g (91%, 42.7 mmol) of the desired product.
1

H NMR (300 MHz, CDCl3): δ 4.25 m, 1H), 4.11 m, 1H), 3.99 br s, 1H), 3.87 d, 2H), 1.63 d,

3H); 13C NMR (75 MHz, CDCl3): δ 65.59, 61.60, 49.17, 25.13. The 1H and 13C NMR data
matched with those previously reported.57,58

Preparation of (E)-3-Bromobut-2-en-1-ol (3).57,58

Diisopropylamine (7.20 mL, 50.6 mmol) dissolved in THF (30 mL) was cooled to -78 oC. A 2.5
M solution of n-BuLi (19 mL, 47 mmol) in hexane was added dropwise, and the reaction was
warmed up to 0 oC and stirred for 45 min. The reaction mixture was then cooled back to -78 oC
and HMPA (1.91 mL, 11.0 mmol) was added to the reaction mixture followed by the 2,398

dibromobutan-1-ol (5.15 g, 22.2 mmol in 25 mL of THF) over 1.5 h. After the addition, the
solution was stirred for 3 h and quenched with a satd solution of NH4Cl. The organic phase was
extracted with CH2Cl2 and purification of the crude product was achieved using column
chromatography with the solvent system 90:10 hexane Et2O to provide 2.00 g (60%, 13.2 mmol)
of (E)-3-bromobut-2-en-1-ol (3) as a colorless oil.
1

H NMR (300 MHz, CDCl3): δ 5.93 (td, 1H), 4.04 (br s, 1H), 3.94(t, 1H), 2.16 (s, 3H); 13C NMR

(75 MHz, CDCl3): δ 130.82, 123.53, 59.61, and 23.53. The 1H and 13C NMR data matched those
previously reported.57,58

Preparation of (E)-3-Methyl-5-(trimethylsilyl)pent-2-en-4-yn-1-ol (4).58

To a solution of 3 (2.00 g, 13.2 mmol) and trimethylsilylacetylene (3.00 mL, 21.1 mmol) in
DMF was added copper(I) iodide (0.45 g, 2.6 mmol) and diisopropylamine (6.90 mL, 39.6
mmol). The reaction was degassed 4 times by a freeze-pump-thaw cycle. PdCl2(PPh3)2 was
added and the degasification was repeated twice. The reaction was stirred at rt for 5 h under an
inert N2 atmosphere and quenched with H2O. The organic phase was washed with H2O and
dried over anhyd MgSO4. Purification of the crude extract was achieved by column
chromatography with the solvent system 90:10 hexane Et2O to give 2.10 g (94%, 12.5 mmol) of
the desired product.
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1

H NMR (300 MHz, CDCl3): δ 5.93 td, 1H), 4.09 t, 2H), 3.34 br s, 1H), 1.73 s, 3H);

13

C

NMR (75 MHz, CDCl3): δ 136.65, 120.19, 107.43, 91.75, 59.59, 17.26, -0.11. The 1H and 13C
NMR data matched with those previously reported.58

I. Synthesis of tert-Butyl(dimethyl){[(2E)-3-methylpent-2-en-4-yn-1yl]oxy}silane (6)
Synthesis of tert-Butyl(dimethyl){[(2E)-3-methyl-5-(trimethylsilyl)pent-2-en-4yn-1-yl]oxy}silane (5)

A solution containing intermediate 4 (0.55 g, 3.3 mmol), imidazole (0.45 g, 6.6 mmol), TBSCl
(0.74 g, 4.9 mmol) and a catalytic amount of DMAP in CH2Cl2 was stirred overnight at rt. The
mixture was quenched with satd NH4Cl and extracted with CH2Cl2, and the organic extracts were
dried over MgSO4. The crude material was purified by column chromatography using the
solvent system 9:1 peroleum ether Et2O to give 0.88 g (3.1 mmol, 94%) of 5 as a yellow oil.
1

H NMR (300 MHz, CDCl3): δ 5.90 t, 1H), 4.15 d, 2H), 1.71 (s, 3H), 0.83 (s, 9H), 0.11 (s, 9H),

0.00 (s, 6H);

13

C NMR (75 MHz, CDCl3): δ 137.97, 118.57, 107.69, 91.06, 59.89,

25.89, 18.27, 17.41, 0.00, -5.25.
100

HR-AccuTOF-DART-MS: Calcd for C15H30OSi2, m/z 282.18352; [M-H]+ m/z 281.17569 (calcd
281.17564). .

Synthesis of tert-Butyl(dimethyl){[(2E)-3-methylpent-2-en-4-yn-1-yl]oxy}silane
(6)

Intermediate 5 (0.88 g, 3.1 mmol) was dissolved in MeOH, and a catalytic amount of K2CO3
was added. The reaction was allowed to stir at rt for 3 h. After complete consumption of the
starting material as revealed on TLC, the reaction was quenched with satd NH4Cl and the
organic phase was extracted with CH2Cl2. This organic extract was dried over MgSO4 and
purified via column chromatography using the solvent system 9:1 petroleum ether Et2O to
give 0.600 g (2.85 mmol, 92%) of 6 as a yellow oil.
1

H NMR (300 MHz, CDCl3): δ 5.97 t, 1H), 4.21 d, 2H), 2.75 s, 1H), 1.76 (s, 3H), 0.88 (s,

9H), 0.05 (s, 6H); 13C NMR (75 MHz, CDCl3): δ 138.34, 117.65, 85.94, 74.62, 59.73, 25.82,
18.20, 17.29, -5.28.
HR-AccuTOF-DART-MS: Calcd for C12H22OSi, m/z 210.14399; [M-H]+ m/z 209.13617 (calcd
209.13544).
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J. Preparation of 1-Hydroxy-9,10-dioxo-9,10-dihydroanthracene-2carbaldehyde (10)
Preparation of 1-(Allyloxy)anthracene-9,10-dione (7).19

1-Hydroxyanthraquinone (2.50 g, 11.1 mmol) was measured and placed in a 1 L round bottom
flask. KI (0.92 g, 5.5 mmol) and K2CO3 (15.6 g, 114 mmol) were also added and dissolved in
400 mL of DMF. Finally, allylbromide was added and the reaction mixture was refluxed at 90
o

C for 4 h. The reaction was monitored by TLC, and upon completion, the mixture was filtered

and the K2CO3 residue was washed with acetone. The solution was concentrated, and the crude
material was purified by column chromatography using the solvent system 9:1 petroleum ether
EtOAc to give 2.70 g (10.2 mmol, 92%) of 7 as a yellow solid.
1

H NMR (300 MHz, CDCl3): δ 8.21 8.13(dd, 2H), 7.87 7.85 (d, 1H), 7.74 7.57 (m, 3H), 7.26

7.23 (d, 1H), 6.16 6.03 (m, 1H), 5.67 5.62 (dd, 1H), 5.37 5.33 (dd, 1H), 4.70 4.69 (d, 2H); 13C
NMR (75 MHz, CDCl3): δ 183.29, 182.01, 159.23, 135.62, 134.94, 134.72, 134.14, 133.10,
132.36, 132.10, 127.14, 126.45, 121.63, 119.85, 119.39, 118.10, 69.99; The 1H and 13C NMR
data matched those previously reported.19
HR-AccuTOF-DART-MS: Calcd for C17H12O3, m/z 264.07864; [M+H]+ m/z 265.08427 (calcd
265.08592).
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Preparation of 2-Allyl-1-hydroxyanthracene-9,10-dione (8).20

A solution containing Na2S2O4 (0.33 g, 1.9 mmol) in 150 mL of H2O and 50 mL of DMF was
heated to 110 oC. To this mixture, was added a solution containing intermediate 7 (0.50 g, 1.9
mmol) in 100 mL of DMF. The reaction was refluxed for about 3 h and monitored by TLC until
complete consumption of the starting material was achieved. After completion of the reaction, it
was cooled for 3 h and crystals precipitated in the flask. The crystals were filtered and dried to
yield 0.48 g (1.8 mmol, 96%) of 8 as a yellow solid.
1

H NMR (300 MHz, CDCl3): δ 12.86 br s, 1H), 8.20 8.15 (dd, 2H), 7.73 7.70 (m, 2H), 7.66

7.63 (d, 1H), 7.46 7.43 d, 1H), 6.05 5.92 (m, 1H), 5.16 (dd, 1H), 5.12 (dd, 1H), 3.46 3.43 (d,
2H); 13C NMR (75 MHz, CDCl3): δ 188.69, 182.03, 160.43, 136.47, 136.29, 134.79, 134.46,
133.90, 133.56, 133.09, 131.44, 127.17, 126.75, 119.21, 117.10, 115.31, 33.74. The 1H and 13C
NMR data matched those previously reported.20
HR-AccuTOF-DART-MS: Calcd for C17H12O3, m/z 264.07864; [M+H]+ m/z 265.08418 (calcd
265.08592).

103

Preparation of (E)-1-Hydroxy-2-(prop-1-en-1-yl)anthracene-9,10-dione (9).22

A solution containing intermediate 8 (0.48 g, 1.8 mmol) and bis(acetonitrile)dichloropalladium
(II) in 75 mL of CH2Cl2 was refluxed for 10 h. The reaction mixture was cooled, washed with
H2O, concentrated and dried with MgSO4. The crude material was purified by flash
chromatography using the solvent system 4:1 CH2Cl2 EtOAc to give 0.47 g (1.8 mmol, 98%) of
9 as an orange solid.
1

H NMR (300 MHz, CDCl3): δ 13.18 br s, 1H), 8.30 m, 1H), 8.28 m, 1H), 7.80 7.78 (m, 2H),

7.77 7.73 (m, 2H), 6.83 6.80 d, 1H), 6.57 6.50 (m, 1H), 1.99 1.98 (d, 3H);

13

C NMR (75

MHz, CDCl3): δ 189.03, 182.04, 159.61, 134.59, 133.90, 133.78, 133.72, 133.26, 132.43,
131.25, 127.26, 126.88, 124.09, 119.51, 115.91, 19.24. The 1H and 13C NMR data matched those
previously reported.22
HR-AccuTOF-DART-MS: Calcd for C17H12O3, m/z 264.07864; [M+H]+ m/z 265.08435 (calcd
265.08592).
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Preparation of 1-Hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde
(10).22

A solution of 9 (0.47 g, 1.8 mmol) dissolved in 100 mL of CH2Cl2 was cooled to -78 oC. O3 was
passed into the solution until it turned greenish-yellow (about 3 h). N2 gas was bubbled through
the solution to ensure removal of the extra O3. After the greenish-yellow color disappeared, 3
mL of (CH3)2S was added, and the reaction mixture was allowed to stir overnight at rt. The
solution was concentrated and the product was purified on a silica gel column with the solvent
system 9:1 petroleum ether EtOAc to give 0.40 g (1.6 mmol, 89%) of 10 as a yellow solid
product.
1

H NMR (300 MHz, CDCl3): δ 13.20 s, 1H), 10.59 s, 1H), 8.32 8.26 (m, 2H), 8.20 8.17(d, 1H),

7.86 7.83 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 188.79, 187.84, 181.69, 164.40, 137.10, 135.35,
135.23, 134.63, 133.23, 132.81, 128.32, 127.64, 127.10, 118.62, 117.36. The 1H and 13C NMR data
matched those previously reported.22
HR-AccuTOF-DART-MS: Calcd for C15H8O4, m/z 252.04226; [M+H]+ m/z 253.04851 (calcd
253.04953).
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K. Synthesis of 2-((S)-1-Hydroxy-1-((R)-oxiran-2-yl)ethyl)-4H-naphtho[2, 3h]chromene-4,7,12-trione (17A)
Synthesis of (E)-2-(6-((tert-Butyldimethylsilyl)oxy)-1-hydroxy-4-methylhex-4en-2-yn-1-yl)-1-hydroxyanthracene-9,10-dione (11)

Intermediate 6 (0.600 g, 2.85 mmol) was dissolved in dry THF and purged with N2 for 15 min.
The temperature of the reaction was reduced to -78 oC and a 2.5M solution of n-BuLi (1.25 mL,
3.13 mmol) in hexanes was added dropwise. The reaction mixture was allowed to slowly warm
up to 0 oC for about 3 h. The temperature of the reaction flask was again reduced to -78 oC, and
intermediate 10 (0.33 g, 1.3 mmol) dissolved in dry THF was quickly added into the reaction
flask via a syringe. The reaction was quickly warmed up to rt and stirred for 1 h. After complete
consumption of the aldehyde as indicated on TLC, the reaction was quenched with satd NH4Cl.
The organic phase was extracted with CH2Cl2, dried with anhyd MgSO4 and concentrated.
Purification of the crude material was achieved with a silica gel column using the solvent system
6.0:3.6:0.4 hexane CH2Cl2 EtOAc to yield 0.35 g (0.76 mmol, 59%) of 11 as a dark-brown oil.
1

H NMR (300 MHz, CDCl3): δ 13.10 s, 1H), 8.22 m, 2H), 7.95 d, 1H), 7.76 (m, 3H), 6.00 (t,

1H), 5.93 (br, 1H), 4.26 (d, 2H), 3.31 (br, 1H), 1.81 (s, 3H), 0.88 (s, 9H), 0.06 (s, 6H); 13C NMR
(125 MHz, CDCl3): δ 188.77, 181.91, 159.76, 138.19, 135.58, 134.81, 134.67, 134.17, 133.47,
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132.95, 132.89, 127.40, 126.89, 119.40, 117.80, 115.87, 89.39, 84.31, 60.18, 59.61, 25.89, 18.31,
17.47, -5.21;
HR-AccuTOF-DART-MS: Calcd for C27H30O5Si, m/z 462.18625; [M-OH]+ m/z 445.18461
(calcd 445.18296).

Synthesis of (E)-2-(6-((tert-Butyldimethylsilyl)oxy)-4-methylhex-4-en-2-ynoyl)1-hydroxyanthracene-9,10-dione (12)

To a solution containing intermediate 11 (0.35 g, 0.76 mmol) in 20 mL of CH2Cl2, was added
MnO2 (1.31 g, 15.1 mmol). The reaction flask was stirred for 4 h, and the mixture was filtered
over celite and concentrated to give 0.34 g (0.74 mmol, 97%) of 12 as a dark-brown oil.
1

H NMR (500 MHz, CDCl3): δ 13.59 s, 1H), 8.29 8.26 d, 1H), 8.25 8.16 m, 2H), 7.79 7.74

(m, 3H), 6.34 (t, 1H), 4.33(d, 2H), 1.89 (s, 3H), 0.88 (s, 9H), 0.07 (s, 6H);

13

C NMR (125 MHz,

CDCl3): δ 189.11, 181.63, 175.19, 162.74, 145.09, 138.99, 136.49, 134.99, 134.61, 132.95,
130.18, 127.39, 127.12, 118.04, 117.31, 116.57, 96.89, 86.16, 60.18, 25.85, 18.29, 16.81, -5.24.
HR-AccuTOF-DART-MS: Calcd for C27H28O5Si, m/z 460.17060; [M+H]+ m/z 461.17843 (calcd
461.17788).
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Synthesis of (E)-2-(4-((tert-Butyldimethylsilyl)oxy)but-2-en-2-yl)-4Hnaphtho[2,3-h] chromene-4,7,12-trione (13)

To a solution of intermediate 12 (0.34 g, 0.74 mmol) in dry DMF (20 mL), was added Cs2CO3 (0.26
g, 0.81 mmol). The reaction was stirred at rt for 1.5 h and quenched with satd NH4Cl. The organic
phase was extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the crude product
was achieved with column chromatography using the solvent system 6.0:3.6:0.4 hexane CH2Cl2
EtOAc to yield 0.21 g (0.46 mmol, 62%) of 13 as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.36 8.33 (d, 1H), 8.09 7.99 m, 3H), 7.72 7.63 m, 2H), 7.27 t,

1H), 6.27 s, 1H), 4.49 4.47 (d, 2H), 1.90 (s, 3H), 0.96 (s, 9H), 0.16 (s, 6H);

13

C NMR (125 MHz,

CDCl3): δ 181.75, 180.12, 176.82, 164.97, 153.72, 139.46, 137.28, 134.44, 133.90, 133.60, 131.76,
131.29, 127.49, 126.92, 126.62, 126.13, 122.46, 121.82, 107.46, 60.77, 25.82, 18.26, 12.50, -5.23;
HR-AccuTOF-DART-MS: Calcd for C27H28O5Si, m/z 460.17060; [M+H]+ m/z 461.17500 (calcd
461.17788).
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Synthesis of (E)-2-(4-Hydroxybut-2-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12trione (14)

A solution of intermediate 13 (0.21 g, 0.46 mmol) dissolved in dry THF was cooled to 0 oC and a
1.0 M solution of TBAF (0.46 mL, 0.46 mmol) in THF was added to the solution. The reaction
mixture was allowed to stir for 45 min and it was quenched with satd NH4Cl. The organic phase
was extracted with CH2Cl2, dried with anhyd MgSO4 and concentrated. Purification of the crude
product was achieved with a silica gel column using the solvent system 6:4 CH2Cl2 EtOAc to
provide 0.13 g (0.37 mmol, 80%) of 14 as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.57 d, 1H), 8.31 d, 1H), 8.26 t, 2H), 7.82 m, 2H), 7.52 t, 1H),

6.49 (s, 1H), 4.59 (d, 2H), 2.05 (s, 3H);

13

C NMR (125 MHz, CDCl3): δ 182.21, 181.07, 171.36,

165.17, 154.15, 137.86, 137.79, 134.74, 134.18, 134.05, 132.12, 131.81, 127.87, 127.82, 127.36,
127.03, 122.91, 122.23, 108.18, 60.17, 12.80
HR-AccuTOF-QStar Elite-MS: Calcd for C21H14O5, m/z 346.041; [M+H]+ m/z 347.0919 (calcd
347.0946).
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Synthesis of (E)-2-(4-Chlorobut-2-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12trione (15)

A solution of intermediate 14 (0.09 g, 0.26 mmol) dissolved in dry THF was cooled to 0 oC. To this
solution was added TEA (1.1 mL, 0.78 mmol) followed by MsCl (0.03 mL, 0.39 mmol), and the
reaction was stirred for 30 min. A satd solution of KCl in H2O and 18-crown-6 (0.34 g, 1.3 mmol)
were added to the reaction mixture and refluxed overnight. After complete consumption of the
starting material as revealed on TLC, the reaction was quenched with satd NH4Cl, extracted with
CH2Cl2 and dried with anhyd MgSO4. Purification of the crude material was achieved with a silica
gel column using the solvent system 8:2 CH2Cl2 EtOAc to yield 0.08 g (0.22 mmol, 85%) of 15 as
a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.59 d, 1H), 8.35 d, 2H), 8.30 d, 1H), 7.84 m, 2H), 7.60 t, 1H),

6.56(s, 1H), 4.43 (d, 2H), 2.14 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 182.26, 181.10, 177.19,
164.55, 154.16, 137.90, 134.76, 134.27, 134.06, 132.38, 132.17, 131.75, 131.40, 127.83, 127.44,
127.06, 123.01, 122.38, 109.10, 39.41, 12.50.
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HR-AccuTOF-QStar Elite-MS: Calcd for C21H13ClO4, m/z 364.0502; [M+H]+ m/z 365.0581 (calcd
365.0585).

Synthesis of 2-((2S,3S)-4-Chloro-2,3-dihydroxybutan-2-yl)-4H-naphtho[2,3h]chromene-4,7,12-trione (16)

A solution of OsO4 (0.01 mL of a 2.5 mol % in t-BuOH), AD-mix-β 0.450 g), and MeSO2NH2
(0.052 g, 0.550 mmol) were dissolved in t-BuOH and H2O (2mL/2mL), and stirred at rt for 1 h. The
resulting solution was cooled to 0 oC by dipping the flask into a cold bath. Intermediate 15 (0.08 g,
0.22 mmol) was dissolved in CH2Cl2 (2 mL) and added to the reaction mixture. The resulting
solution was stirred for 24 h with monitoring by TLC. After complete consumption of the starting
material, the reaction was quenched with satd Na2S2O3. The organic phase was extracted with
CH2Cl2 , washed with brine, dried with MgSO4 and concentrated. Purification of the crude product
was achieved with a silica gel column using the solvent system 1:1 hexane EtOAc to provide 0.070
g (0.175 mmol, 80%) of 16 as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.61 8.59 d, 1H), 8.36 8.35 (d, 1H), 8.34 8.29 (m, 2H), 7.85 (m,

2H), 6.79 (s, 1H), 4.45 4.43 (dd, 1H), 4.00 3.97 dd, 1H), 3.80 3.76 (m, 2H), 3.11 (s, 1H), 1.76 (s,
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3H); ); 13C NMR (125 MHz, CDCl3): δ 182.02, 181.62, 176.65, 172.78, 154.06, 137.72, 134.87,
134.40, 134.07, 132.21, 132.20, 128.04, 127.55, 127.21, 123.40, 122.26, 109.01, 75.40, 75.34,
45.78, 23.81.
HR-AccuTOF-QStar Elite-MS: Calcd for C21H14O5, m/z 398.0557; [M+H]+ m/z 399.0630 (calcd
399.0603).

Synthesis of 2-((S)-1-Hydroxy-1-((R)-oxiran-2-yl)ethyl)-4H-naphtho[2, 3h]chromene-4,7,12-trione (17A)

To a solution of intermediate 16 (0.030 g, 0.075 mmol) dissolved in 10 mL of CH2Cl2 was added
DBU (0.012 mL, 0.079 mmol) dropwise. The resulting solution was stirred at rt for 4 h. The
reaction was monitored by TLC and after complete consumption of the starting material, the
reaction was quenched with H2O and the organic phase was extracted with CH2Cl2, dried with
MgSO4 and concentrated. Purification of the crude product was achieved using a silica gel column
with the solvent system 7:3 CH2Cl2 EtOAc to provide 0.018 g (0.049 mmol, 66%) of the final
compound 17A as a yellow solid.
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1

H NMR (500 MHz, CDCl3): 1H NMR (500 MHz, CDCl3): δ 8.64 8.61 d, 1H), 8.39 8.36 (d, 1H),

8.33 8.30 dd, 2H), 7.85 m, 2H), 6.74 s, 1H), 4.00 3.98 dd, 1H), 3.05 3.03 m, 1H), 2.99 2.96
(m, 1H), 2.83 (s, 1H), 1.77 (s, 1H);

13

C NMR (125 MHz, CDCl3): δ 182.18, 181.17, 176.78,

172.57, 154.31, 137.74, 134.79, 134.21, 134.18, 132.22, 132.01, 128.04, 127.30, 127.18, 123.27,
122.45, 108.42, 70.94, 55.51, 43.76, 23.09.
HR-AccuTOF-QStar Elite-MS: Calcd for C21H14O5, m/z 362.0790; [M+H]+ m/z 363.0869 (calcd
363.0873).

L. Synthesis of 2-((R)-1-Hydroxy-1-((S)-oxiran-2-yl) ethyl)-4H-naphtho [2, 3h]chromene-4,7,12-trione (17A’)
Synthesis of 2-((2R, 3R)-4-chloro-2, 3-dihydroxybutan-2-yl)-4H-naphtho[2, 3h]chromene-4,7,12-trione (18)

A solution of OsO4 (0.01 mL of a 2.5 mol % in t-BuOH), AD-mix-α (0.450 g), and MeSO2NH2
(0.052 g, 0.550 mmol) were dissolved in t-BuOH and H2O (2mL/2mL), and stirred at rt for 1 h.
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The resulting solution was cooled to 0 oC by dipping the flask into a cold bath. Intermediate 15
(0.08 g, 0.22 mmol) was dissolved in CH2Cl2 (2 mL) and added to the reaction mixture. The
resulting solution was stirred for 48 h with monitoring by TLC. After complete consumption of the
starting material, the reaction was quenched with satd Na2S2O3. The organic phase was extracted
with CH2Cl2, washed with brine, dried with MgSO4 and concentrated. Purification of the crude
product was achieved with a silica gel column using the solvent system 1:1 hexane EtOAc to
provide 0.060 g (0.150 mmol, 68.4%) of 18 as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.62 8.60 (d, 1H), 8.37 8.36 (d, 2H), 8.35 8.30 m, 2H), 7.86 m,

2H), 6.80 s, 1H), 4.46 4.44 (dd, 1H), 4.01 3.98(dd, 1H), 3.80 (m, 2H), 1.76 (s, 3H); ); 13C NMR
(125 MHz, CDCl3): δ 182.02, 181.61, 176.67, 172.84, 154.07, 137.72, 134.88, 134.40, 134.07,
132.21, 132.19, 128.03, 127.55, 127.21, 123.40, 122.26, 109.01, 75.41, 75.36, 45.78, 23.81.
HR-AccuTOF-QStar Elite-MS: Calcd for C21H14O5, m/z 398.0557; [M+H]+ m/z 399.0630 (calcd
399.0603).
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Synthesis of 2-((R)-1-Hydroxy-1-((S)-oxiran-2-yl) ethyl)-4H-naphtho [2, 3h]chromene-4,7,12-trione (17A’)

To a solution of intermediate 18 (0.030 g, 0.075 mmol) dissolved in 10 mL of CH2Cl2 was added
DBU (0.012 mL, 0.079 mmol) dropwise. The resulting solution was stirred at rt for 4 h. The
reaction was monitored by TLC, and after complete consumption of the starting material, the
reaction was quenched with water and the organic phase was extracted with CH2Cl2, dried with
MgSO4 and concentrated. Purification of the crude product was achieved using a silica gel column
with the solvent system 7:3 CH2Cl2 EtOAc to provide 0.018g (0.049 mmol, 66%) of the final
compound 17A’ as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.64 8.61 d, 1H), 8.39 8.36 (d, 1H), 8.33 8.30 dd, 2H), 7.85 m,

2H), 6.74 s, 1H), 3.99 3.97 dd, 1H), 3.05 3.02 (m, 1H), 2.98 2.95 (m, 1H), 2.82 (s, 1H), 1.77 (s,
1H);

13

C NMR (125 MHz, CDCl3): δ 182.18, 181.17, 176.78, 172.57, 154.31, 137.74, 134.79,

134.21, 134.18, 132.22, 132.01, 128.04, 127.30, 127.18, 123.27, 122.45, 108.42, 70.94, 55.51,
43.76, 23.09.
HR-AccuTOF-QStar Elite-MS: Calcd for C21H14O5, m/z 362.0790; [M+H]+ m/z 363.0869 (calcd
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363.0873).

M. Synthesis of 2-((S)-1-Hydroxy-1-((S)-oxiran-2-yl)ethyl)-4H-naphtho[2,3h]chromene-4,7,12-trione (17B)
Synthesis of 2-((2S, 3R)-4-((tert-Butyldimethylsilyl)oxy)-2,3-dihydroxybutan-2yl)-4H-naphtho[2, 3-h]chromene-4,7,12-trione (20)

A solution of OsO4 (0.07 mL of a 2.5 mol % in t-BuOH), AD-mix-β 1.0 g), and MeSO2NH2 (0.16
g, 1.7 mmol) were dissolved in t-BuOH and H2O (5mL/5mL), and stirred at rt for 2 h. The resulting
solution was cooled to 0 oC by dipping the flask into a cold bath. Intermediate 13 (0.31 g, 0.67
mmol) was dissolved in CH2Cl2 (2 mL) and added to the reaction mixture. The resulting solution
was stirred for 24 h while monitoring with TLC. After complete consumption of the starting
material, the reaction was quenched with satd Na2S2O3. The organic phase was extracted with
CH2Cl2 and washed with brine. Purification of the crude was achieved with a silica gel column
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using the solvent system 8:2 hexane EtOAc to provide 0.320 g (0.647 mmol, 96.5%) of 20 as a
yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.66 8.65 d, 1H), 8.39 8.37 d, 1H), 8.33 8.30 (m, 2H), 7.86 7.84

(m, 2H), 6.86 (s, 1H), 4.51 (s, 1H), 4.44 4.42 d, 1H), 4.13 m, 1H), 4.08 m, 1H), 3.73 3.70 (dd,
1H), 1.75(s, 1H), 0.89 (s, 9H), 0.08 (s, 3H), 0.03(s, 3H);

13

C NMR (125 MHz, CDCl3): δ 182.02,

181.97, 176.37, 174.42, 154.17, 137.64, 134.85, 134.49, 134.02, 132.50, 132.23, 128.19, 127.63,
127.19, 123.37, 122.10, 109.32, 76.30, 74.50, 65.39, 25.74, 24.98, 18.05, -5.64, -5.75.
HR-AccuTOF-DART-MS: Calcd for C27H30O7Si, m/z 494.17608; [M+H]+ m/z 495.18335 (calcd
495.18025).

Synthesis of 2-((4S,5R)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-4-methyl-2oxido-1,3,2-dioxathiolan-4-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (22).

A solution of intermediate 20 (0.17 g, 0.34 mmol) dissolved in 15 mL of CH2Cl2, was cooled to 0
o

C. To this solution was added TEA (0.288 mL, 2.06 mmol) dropwise. This was followed by the
117

addition of SOCl2 (0.75 mL, 1.0 mmol) dropwise and the resulting mixture was allowed to stir at 0
o

C for 1.5 h. After complete consumption of the starting material as revealed on TLC, the reaction

was quenched with H2O. The organic phase was extracted with CH2Cl2, dried with anhyd MgSO4
and concentrated. Purification of the crude material was achieved with a silica gel column using the
solvent system 7:3 hexane EtOAc to give 0.17 g (0.31 mmol, 91.2%) of 22 as a yellow solid
product.
1

H NMR (500 MHz, CDCl3): δ 8.62 8.59 d, 1H), 8.41 8.38 d, 1H), 8.33 8.26 d, 2H), 7.86 m,

2H), 6.70 s, 1H), 5.22 5.17 (dd, 1H), 4.48 4.42 (dd, 1H), 4.18 4.12 (m, 1H), 2.10 (s, 3H), 0.96 s,
9H), 0.18 0.16 (d, 6H);

13

C NMR (125 MHz, CDCl3): δ 182.04, 180.67, 176.31, 168.19, 154.13,

137.95, 134.91, 134.21, 134.19, 132.16, 131.85, 127.84, 127.26, 127.20, 123.66, 122.59, 108.88,
88.40, 87.11, 62.05, 25.77, 20.35, 18.23, -5.43, -5.51. ;
HR-AccuTOF-DART-MS: Calcd for C27H28O8SSi, m/z 540.12742; [M+H]+ m/z 541.13524 (calcd
541.13449).
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Synthesis of 2-((4S,5R)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-4-methyl-2,2dioxido-1,3,2-dioxathiolan-4-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (23)

A solution of intermediate 22 (0.17 g, 0.31 mmol) dissolved in CCl4 and CH3CN (5 mL/5 mL), was
cooled to 0 oC. To this solution was added RuCl3∙3H2O (4.11 mg, 0.016 mmol). This was followed
by the addition of NaIO4 (0.10 g, 0.47 mmol) and H2O (3.0 mL). The resulting reaction mixture
was allowed to stir at 0 oC for 45 min. After complete consumption of the starting material as
revealed on TLC, Et2O was added to the reaction flask and the organic phase was extracted with
Et2O. This organic extract was dried over MgSO4 and purification was achieved with a silica gel
column using the solvent system 7:3 hexane EtOAc to give 0.16 g (0.29 mmol, 92.7%) of 23 as a
yellow solid product.
1

H NMR (500 MHz, CDCl3): δ 8.59 8.56 (d, 1H), 8.38 8.36 (d, 1H), 8.30 8.24 (m, 2H), 7.85 (m,

2H), 6.81 s, 1H), 5.40 5.37 (dd, 1H), 4.60 4.54 dd, 1H), 4.35 4.28 (m, 1H), 2.08 (s, 3H), 0.88 (s,
9H), 0.13 (d, 6H);

13

C NMR (125 MHz, CDCl3): δ 181.76, 180.88, 175.80, 164.62, 153.92, 137.97,

134.98, 134.43, 133.95, 132.06, 132.03, 127.84, 127.27, 127.25, 123.92, 122.35, 109.45, 88.24,
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86.42, 60.37, 25.64, 19.59, 18.19, -5.51, -5.53.
HR-AccuTOF-DART-MS: Calcd for C27H28O9SSi, m/z 556.12233; [M+H]+ m/z 557.13015 (calcd
557.12913).

Synthesis of 2-((2S,3S)-2,3-dihydroxy-4-iodobutan-2-yl)-4H-naphtho[2,3h]chromene-4,7,12-trione (25)

To a solution of intermediate 23 (0.15 g, 0.27 mmol) dissolved in THF, was added TBAF∙3H2O
(0.09 g, 0.28 mmol). The resulting solution was allowed to stir for 45 min. After complete
conversion of the starting material to intermediate 24 (revealed as a baseline on TLC), NaI (0.24 g,
1.6 mmol) dissolved in 1 mL of H2O was added to the flask and the mixture was allowed to stir for
3 h. Finally, a solution of 0.1 M H2SO4 in H2O was added to the reaction flask, and the mixture
was stirred for an additional 2 h. The reaction was quenched with H2O. The organic phase was
extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the crude material was
achieved with a silica gel column using the solvent system 7:3 CH2Cl2 EtOAc to give 0.08 g (0.16
mmol, 60%) of 23 as a light yellow solid product.
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1

H NMR (500 MHz, CDCl3): δ 8.63 8.62 (d, 1H), 8.39 8.38 (d, 1H), 8.34 8.31 m, 2H), 7.89 7.83

m, 2H), 6.73 s, 1H), 4.29 4.27 (dd, 1H), 3.51 3.48 (dd, 1H), 3.30 (t, 1H), 1.79 (s, 3H).;

13

C NMR

(125 MHz, CDCl3): δ 182.00, 181.59, 176.46, 170.93, 154.06, 137.83, 134.90, 134.42, 134.10,
132.22, 132.19, 128.00, 127.57, 127.23, 123.52, 122.34, 109.73, 76.68, 75.15, 23.64, 8.27.;
HR-AccuTOF-DART-MS: Calcd for C21H15IO6, m/z 489.99133; [M+H]+ m/z 490.99962 (calcd
490.99916).

Synthesis of 2-((S)-1-Hydroxy-1-((S)-oxiran-2-yl)ethyl)-4H-naphtho[2,3h]chromene-4,7,12-trione (17B)

To a solution of intermediate 25 (0.06 g, 0.12 mmol) dissolved in dry CH2Cl2 at rt was added
DBU dropwise. The resulting solution was stirred at rt for 1 h while monitoring with TLC. After
complete consumption of the starting material, the reaction was quenched with ice-water. The
organic phase was extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the crude
product was achieved using a silica gel column with the solvent system 7:3 CH2Cl2 EtOAc to
provide 0.035 g (0.097 mmol, 80%) of the final compound 26 as a yellow solid.
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1

H NMR (500 MHz, CDCl3): δ 8.63 8.61 d, 1H), 8.38 8.36 d, 1H), 8.33 8.30(m, 2H), 7.85(m, 2H)

6.71 (s, 1H), 3.78 3.76 dd, 1H), 2.95 2.92 (m, 1H), 2.81 (m, 1H), 2.65 (s, 1H), 1.90 (s, 3H);

13

C

NMR (125 MHz, CDCl3): δ 182.19, 181.13, 176.75, 171.03, 154.24, 137.67, 134.84, 134.19,
132.17, 131.98, 128.10, 127.32, 127.17, 123.26, 122.42, 108.21, 70.77, 56.10, 44.13, 25.64.
HR-AccuTOF-DART-MS: Calcd for C21H14O6, m/z 362.07904; [M+H]+ m/z 363.08631 (calcd
363.08475).

N. Synthesis of 2-((R)-1-Hydroxy-1-((R)-oxiran-2-yl)ethyl)-4Hnaphtho[2,3-h]chromene-4,7,12-trione (17B’)
Synthesis of 2-((2R, 3S)-4-((tert-Butyldimethylsilyl)oxy)-2,3-dihydroxybutan-2yl)-4H-naphtho[2, 3-h]chromene-4,7,12-trione (21)

A solution of OsO4 (0.07 mL of a 2.5 mol % in t-BuOH), AD-mix-α (1.0 g), and MeSO2NH2 (0.16
g, 1.7 mmol) were dissolved in t-BuOH and H2O (5mL/5mL), and stirred at rt for 2 h. 0.07 mL of a
The resulting solution was cooled to 0 oC by dipping the flask into a cold bath. Intermediate 13
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(0.31 g, 0.67 mmol) was dissolved in CH2Cl2 (2 mL) and added to the reaction mixture. The
resulting solution was stirred for 48 h while monitoring with TLC. After complete consumption of
the starting material, the reaction was quenched with satd Na2S2O3. The organic phase was
extracted with CH2Cl2 and washed with brine. Purification of the crude product was achieved with
a silica gel column using the solvent system 8:2 hexane EtOAc to provide 0.310 g (0.627 mmol,
93.5%) of 21 as a yellow solid.
1

H NMR (500 MHz, CDCl313C NMR (125 MHz, CDCl3) δ 8.65 8.63 d, 1H), 8.37 8.35 d, 1H),

8.32 8.29 (m, 2H), 7.84 (m, 2H), 6.85 (s, 1H), 4.50 (s, 1H), 4.42 4.40 d, 1H), 4.13 m, 1H), 4.08
m, 1H), 3.74 3.71 (dd, 1H), 1.74 (s, 1H), 0.88 (s, 9H), 0.07 (s, 3H), 0.03(s, 3H); : δ 182.02,
181.97, 176.37, 174.42, 154.17, 137.64, 134.85, 134.49, 134.02, 132.50, 132.23, 128.19, 127.63,
127.19, 123.37, 122.10, 109.32, 76.30, 74.50, 65.39, 25.74, 24.98, 18.05, -5.64, -5.75.
HR-AccuTOF-DART-MS: Calcd for C27H30O7Si, m/z 494.17608; [M+H]+ m/z 495.18335 (calcd
495.18025).
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2-((4R,5S)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-4-methyl-2-oxido-1,3,2dioxathiolan-4-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (27)

A solution of intermediate 21 (0.17 g, 0.34 mmol) dissolved in 15 mL of CH2Cl2 was cooled to 0
o

C. To this solution was added TEA (0.288 mL, 2.06 mmol) dropwise. This was followed by the

addition of SOCl2 (0.75 mL, 1.0 mmol) dropwise, and the resulting mixture was allowed to stir at 0
o

C for 1.5 h. After complete consumption of the starting material as revealed on TLC, the reaction

was quenched with H2O. The organic phase was extracted with CH2Cl2, dried with anhyd MgSO4
and concentrated. Purification of the crude material was achieved with a silica gel column using
the solvent system 7:3 hexane EtOAc to give 0.17 g (0.31 mmol, 91.2%) of 22 as a yellow solid
product.
1

H NMR (500 MHz, CDCl3): δ 8.61 8.60 d, 1H), 8.40 8.38 d, 1H), 8.32 8.27 d, 2H), 7.88 7.84
m, 2H), 6.70 s, 1H), 5.21 5.18 (dd, 1H), 4.47 4.43 (dd, 1H), 4.17 4.13 (m, 1H), 2.10 (s, 3H),

0.96 s, 9H), 0.18 0.16 (d, 6H);

13

C NMR (125 MHz, CDCl3): δ 182.04, 180.67, 176.31, 168.19,

154.13, 137.95, 134.91, 134.21, 134.19, 132.16, 131.85, 127.84, 127.26, 127.20, 123.66, 122.59,
108.88, 88.40, 87.11, 62.05, 25.77, 20.35, 18.23, -5.43, -5.51. ;
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HR-AccuTOF-DART-MS: Calcd for C27H28O8SSi, m/z 540.12742; [M+H]+ m/z 541.13524 (calcd
541.13449).

Synthesis of 2-((4R,5S)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-4-methyl-2,2dioxido-1,3,2-dioxathiolan-4-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (28)

A solution of intermediate 27 (0.17 g, 0.31 mmol) dissolved in CCl4 and CH3CN (5mL/5 mL), was
cooled to 0 oC. To this solution was added RuCl3∙3H2O (4.11 mg, 0.016 mmol). This was followed
by the addition of NaIO4 (0.10 g, 0.47 mmol) and H2O (3.0 mL). The resulting reaction mixture
was allowed to stir at 0 oC for 45 min. After complete consumption of the starting material as
revealed on TLC, Et2O was added to the reaction flask and the organic phase was separated. This
organic extract was dried over MgSO4, and purification was achieved with a silica gel column using
the solvent system 7:3 hexane EtOAc to give 0.16 g (0.29 mmol, 92.7%) of 23 as a yellow solid
product.
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1

H NMR (500 MHz, CDCl3): δ 8.59 8.56 (d, 1H), 8.38 8.36 (d, 1H), 8.30 8.24 (m, 2H), 7.85 (m,

2H), 6.81 s, 1H), 5.40 5.37 (dd, 1H), 4.60 4.54 dd, 1H), 4.35 4.28 (m, 1H), 2.08 (s, 3H), 0.88 (s,
9H), 0.13 (d, 6H);

13

C NMR (125 MHz, CDCl3): δ 181.76, 180.88, 175.80, 164.62, 153.92, 137.97,

134.98, 134.43, 133.95, 132.06, 132.03, 127.84, 127.27, 127.25, 123.92, 122.35, 109.45, 88.24,
86.42, 60.37, 25.64, 19.59, 18.19, -5.51, -5.53.
HR-AccuTOF-DART-MS: Calcd for C27H28O9SSi, m/z 556.12233; [M+H]+ m/z 557.13015 (calcd
557.12913).

2-((2R,3S)-2,3-dihydroxy-4-iodobutan-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12trione (30)

To a solution of intermediate 28 (0.15 g, 0.27 mmol) dissolved in THF, was added TBAF∙3H2O
(0.09 g, 0.28 mmol). The resulting solution was allowed to stir for 45 min. After complete
conversion of the starting material to intermediate 29 (revealed as a baseline on TLC), NaI (0.24 g,
1.6 mmol) dissolved in 1 mL of H2O was added to the flask and the reaction was allowed to stir for
3 h. Finally, a solution of 0.1 M H2SO4 in H2O was added to the reaction flask and stirred for an
126

additional 2h. The reaction was quenched with H2O. The organic phase was extracted with CH2Cl2
and dried with anhyd MgSO4. Purification of the crude material was achieved with a silica gel
column using the solvent system 7:3 CH2Cl2 EtOAc to give 0.08 g (0.16 mmol, 60%) of 30 as a
light yellow solid product. ;
1

H NMR (500 MHz, CDCl3): δ 8.63 8.62 (d, 1H), 8.39 8.38 (d, 1H), 8.34 8.31 m, 2H), 7.89 7.83
m, 2H), 6.73 s, 1H), 4.29 4.27 (dd, 1H), 3.51 3.48 (dd, 1H), 3.30 (t, 1H), 1.79 (s, 3H).;

13

C NMR

(125 MHz, CDCl3): δ 182.00, 181.59, 176.46, 170.93, 154.06, 137.83, 134.90, 134.42, 134.10,
132.22, 132.19, 128.00, 127.57, 127.23, 123.52, 122.34, 109.73, 76.68, 75.15, 23.64, 8.27.;HRAccuTOF-DART-MS: Calcd for C21H15IO6, m/z 489.99133; [M+H]+ m/z 490.99962 (calcd
490.99916).

Synthesis of 2-((R)-1-Hydroxy-1-((R)-oxiran-2-yl)ethyl)-4H-naphtho[2,3h]chromene-4,7,12-trione (17B’)

127

To a solution of intermediate 30 (0.06 g, 0.12 mmol) dissolved in dry CH2Cl2 at rt, was added
DBU dropwise. The resulting solution was stirred at rt for 1 h while monitoring with TLC.
After complete consumption of the starting material, the reaction was quenched with ice-water.
The organic phase was extracted with CH2Cl2 and dried with anhyd MgSO4. Purification of the
crude product was achieved using a silica gel column with the solvent system 7:3 CH2Cl2
EtOAc to provide 0.035 g (0.097 mmol, 80%) of the final compound 17B’ as a yellow solid.
1

H NMR (500 MHz, CDCl3): δ 8.63 8.61 d, 1H), 8.38 8.35 d, 1H), 8.32 8.30(m, 2H), 7.85(m, 2H)

6.71 (s, 1H), 3.78 3.76 dd, 1H), 2.95 2.93 (m, 1H), 2.83 2.80 (m, 1H), 2.69 (s, 1H), 1.90 (s, 3H);
13

C NMR (125 MHz, CDCl3): δ 182.17, 181.11, 176.74, 171.05, 154.24, 137.68, 134.83, 134.18,

132.18, 131.97, 128.09, 127.31, 127.16, 123.25, 122.42, 108.22, 70.78, 56.11, 44.13, 25.61.
HR-AccuTOF-DART-MS: Calcd for C21H14O6, m/z 362.07904; [M+H]+ m/z 363.08631 (calcd
363.08475).
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1

H NMR spectrum (300 MHz, CDCl3) of 1-(Allyloxy)anthracene-9,10-dione (7)
136

13

C NMR spectrum (75 MHz, CDCl3) of 1-(Allyloxy)anthracene-9,10-dione (7)
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1

H NMR spectrum (300 MHz, CDCl3) of 2-allyl-1-hydroxyanthracene-9,10-dione (8)
138

13

C NMR spectrum (75 MHz, CDCl3) of 2-allyl-1-hydroxyanthracene-9,10-dione (8)
139

1

H NMR spectrum (300 MHz, CDCl3) of (E)-1-hydroxy-2-(prop-1-en-1-yl)anthracene-9,10-dione (9)
140

13

C NMR spectrum (75 MHz, CDCl3) of (E)-1-hydroxy-2-(prop-1-en-1-yl)anthracene-9,10-dione (9)
141

1

H NMR spectrum (300 MHz, CDCl3) of 1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde (10)
142

13

C NMR spectrum (75 MHz, CDCl3) of 1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde (10)
143

1

H NMR spectrum (500 MHz, CDCl3) of 2-(1,4-dihydroxy-4-methylhex-5-en-2-yn-1-yl)-1-hydroxyanthracene-9,10-dione (54)
144

13

C NMR spectrum (125 MHz, CDCl3) of 2-(1,4-dihydroxy-4-methylhex-5-en-2-yn-1-yl)-1-hydroxyanthracene-9,10-dione (54)
145

1

H NMR spectrum (500 MHz, CDCl3) of 2-(2-hydroxybut-3-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (55)
146

13

C NMR spectrum (125 MHz, CDCl3) of 2-(2-hydroxybut-3-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (55)
147

1

H NMR spectrum (300 MHz, CDCl3) of 2-phenylbut-3-en-2-ol (63)
148

13

C NMR spectrum (75 MHz, CDCl3) of 2-phenylbut-3-en-2-ol (63)
149

1

H NMR spectrum (300 MHz, CDCl3) of 1-phenylprop-2-en-1-ol (58)
150

13

C NMR spectrum (75 MHz, CDCl3) of 1-phenylprop-2-en-1-ol (58)
151

1

H NMR spectrum (300 MHz, CDCl3) of (R)-((S)-oxiran-2-yl)(phenyl)methanol (59)
152

13

C NMR spectrum (75 MHz, CDCl3) of (R)-((S)-oxiran-2-yl)(phenyl)methanol (59)
153

1

H NMR spectrum (300 MHz, CDCl3) of (S)-oxiran-2-yl(phenyl)methanone (60)
154

13

C NMR spectrum (75 MHz, CDCl3) of (S)-oxiran-2-yl(phenyl)methanone (60)
155

1

H NMR spectrum (300 MHz, CDCl3) of (S)-1-((S)-oxiran-2-yl)-1-phenylethanol (61)
156

13

C NMR spectrum (75 MHz, CDCl3) of (S)-1-((S)-oxiran-2-yl)-1-phenylethanol (61)
157

1

H NMR spectrum (300 MHz, CDCl3) of 5-(trimethylsilyl)pent-1-en-4-yn-3-ol (32)
158

13

C NMR spectrum (75 MHz, CDCl3) of 5-(trimethylsilyl)pent-1-en-4-yn-3-ol (32)
159

1

H NMR spectrum (300 MHz, CDCl3) of tert-butyldimethyl((5-(trimethylsilyl)pent-1-en-4-yn-3-yl)oxy)silane (33)
160

13

C NMR spectrum (75 MHz, CDCl3) of tert-butyldimethyl((5-(trimethylsilyl)pent-1-en-4-yn-3-yl)oxy)silane (33)
161

1

H NMR spectrum (300 MHz, CDCl3) of tert-butyldimethyl(pent-1-en-4-yn-3-yloxy)silane (34)
162

13

C NMR spectrum (75 MHz, CDCl3) of tert-butyldimethyl(pent-1-en-4-yn-3-yloxy)silane (34)
163

1

H NMR spectrum (300 MHz, CDCl3) of 2-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxyhex-5-en-2-yn-1-yl)-1-hydroxyanthracene9,10-dione (35)
164

13

C NMR spectrum (75 MHz, CDCl3) of 2-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxyhex-5-en-2-yn-1-yl)-1-hydroxyanthracene9,10-dione (35)
165

1

H NMR spectrum (300 MHz, CDCl3) of 2-methylbut-1-en-3-yne (37)
166

13

C NMR spectrum (75 MHz, CDCl3) of 2-methylbut-1-en-3-yne (37)
167

1

H NMR spectrum (500 MHz, CDCl3) of 1-hydroxy-2-(1-hydroxy-4-methylpent-4-en-2-yn-1-yl)anthracene-9,10-dione (38)
168

13

C NMR spectrum (125 MHz, CDCl3) of 1-hydroxy-2-(1-hydroxy-4-methylpent-4-en-2-yn-1-yl)anthracene-9,10-dione (38)
169

1

H NMR spectrum (500 MHz, CDCl3) of 1-hydroxy-2-(4-methylpent-4-en-2-ynoyl)anthracene-9,10-dione (39)
170

13

C NMR spectrum (125 MHz, CDCl3) of 1-hydroxy-2-(4-methylpent-4-en-2-ynoyl)anthracene-9,10-dione (39)
171

1

H NMR spectrum (500 MHz, CDCl3) of 2-(prop-1-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (40)
172

13

C NMR spectrum (125 MHz, CDCl3) of 2-(prop-1-en-2-yl)-4H-naphtho[2,3-h]chromene-4,7,12-trione (40)
173

1

H NMR spectrum (300 MHz, CDCl3) of (E)-but-2-en-1-ol (1)
174

13

C NMR spectrum (75 MHz, CDCl3) of (E)-but-2-en-1-ol (1)
175

1
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